Mandard TRG
Dworak TRG Treatment response was assessed in all sections and both systems were applied by two independent pathologists. Results: Twenty cases showed partial pathological response; 1 showed complete pathological response. Chemotherapeutic effect was characterised by fibrosis, foamy macrophages and nuclear enlargement. "Free" psammoma bodies were a feature, specific to post-NAC serous carcinoma , analogous to the presence of acellular mucin in post-NAC rectal tumours.
Mandard TRG showed interobserver agreement in 18 of 21 cases (85.7%); for Dworak TRG there was agreement in 17 of 21 cases (80.9%). 18 cases with extra-ovarian deposits demonstrated a better treatment response in extraovarian deposits in comparison to the ovary, 9/18 cases (50%). Conclusions: Mandard TRG was developed for oesophageal carcinoma but is already widely applied to assess to lower GI Adenocarcinomas and occasionally breast cancers. In this study, Mandard TRG was applicable and reproducible in ovarian serous adenocarcinomas .
Recurrent Granulosa Cell Tumors: Clinicopathological and Molecular Markers
Eman Abdulfatah, Sharif Sakr, Zaid Al-Wahab, Haleema Saeed, Sumi Thomas, Baraa Alosh, Attah Saleh, Rouba Ali-Fehmi, Sudeshna Bandyopadhyay. Wayne State University, Karmanos Cancer Institute, Detroit, MI. Background: GCT comprise 2-5% of ovarian neoplasms, with unpredictable patterns of recurrence. The HER family, GATA4 and SMAD3 genes are reportedly involved in granulosa cell proliferation and apoptosis and may serve as new predictors of recurrence. The aim of this study was to evaluate the determinants of recurrence in GCT from a large single institution cohort. Design: 137 patients diagnosed with GCT (1975 GCT ( -2014 were identified. Clinicopathological variables were obtained from EMR and pathologic records. Immunohistochemical staining (IHC) for calretinin, inhibin, HER 2, CD56, SMAD3, GATA4 was done on tumor tissue microarray for 88 GCT cases. Each marker was scored for % and intensity and H-score was established combining both. Results: Of 137 GCT cases, 124 (90.5%) were Adult (AGCT) and 13 (9.5%) were Juvenile (JGCT). 12/137 (8.8%) patients had recurrence. AGCT recurred in 10/124 (8.0%) vs. 2/13 (15.3%) JGCT. Recurrence was significantly more frequent in Stage III and Caucasian (CA) patients. Recurrence was more frequent in tumor size ≥ 5cm and mitoses > 2/10hpf. Significantly increased expression of HER-2, SMAD3 and CD56 was seen in the recurrent cases. No significant differences were noted in the expression of Calretinin and Inhibin and VEGF. 
Conclusions:
Recurrence is significantly higher in CA and stage III patients. JGCT show a higher tendency to recur, suggesting an aggressive course. CD56 may prove to be a prognostic marker for recurrent GCT. Expression of HER-2 and SMAD3 may present potential targets for novel therapy.
number changes of CCNE1 was assessed by two-color fluorescence in situ hybridization (FISH) in the tumors showing cyclin E1 overexpression. ARID1A loss and TERT (telomerase reverse transcriptase) mutation data were also available for comparison. Results: Cyclin E1 overexpression occurred in 22 (25.3%) of 89 ovarian clear cell carcinomas but none in endometrioid carcinomas. CCNE1 FISH in clear cell carcinomas revealed that 16.2% had an increased CCNE1 copy number. All cases with CCNE1 amplification demonstrated an intense immunoreactivity of cyclin E1. CCNE1 amplification positively correlated with TERT promoter mutation (p= 0.015) which was thought to be one of the molecular mechanisms to increase TERT expression and maintain telomere length in cancer cells. There was no correlation between CCNE1 amplification and loss of ARID1A protein, a characteristic feature of ovarian clear cell carcinoma. Conclusions: Gene amplification and upregulation of CCNE1 occur in ovarian clear cell carcinoma but not in ovarian endometrioid carcinoma, suggesting both types of ovarian cancer develop through distinct molecular pathways. CCNE mutations along with TERT promoter mutations occurring in progression may be responsible for clear cell carcinoma aggressiveness.
polyps, 2 chronic vulvitis, 4 pseudoepitheliomatous hyperplasia and 3 extramammary Paget's disease. The pattern of immunohistochemical expression of CK17 was evaluated. In intraepithelial lesions, positive staining for CK17 was considered as either peripheral staining (basal or outer third) or as diffuse staining while cases were considered negative if they displayed complete absence of CK17 expression, showed staining limited to the surface (suprabasal or inner two thirds), or if expression was present in <10% of basal cells. For invasive carcinomas, expression of CK17 was evaluated in the invasive component. Statistical analysis was performed using Fisher's exact test. Statistical significance was defined as p value <0.05. Results: Three of 52 cases of VIN (5.8%), 2 of 17 non-neoplastic (NN) cases (11.7%) and 25 of 36 cases of squamous cell carcinoma (SCC) (69.4%) showed positive staining for CK17. There was a statistically significant difference between NN and SCC (p<0.05) and between VIN and SCC cases (p<0.05). Twelve of 20 (60%) cases of SISCC and 13 of 16 cases (81.2%) of ISCC showed positive staining for CK17 in the invasive component. There was no statistically significant difference between SISCC and ISCC (p=0.27) . In 10 of 12 SISCC cases, CK17 positivity was confined to the invasive component while the overlying VIN was negative for CK17. Additionally, cases of extramammary Paget's disease showed negative staining of the neoplastic cells for CK17 while the surrounding keratinocytes revealed diffuse positivity with this marker.
In concordance to what has been reported in anal squamous lesions, CK17 may be an useful adjunct for the diagnosis of squamous cell carcinoma of the vulva, especially in the setting of early stromal invasion. Dina Bassiouny, Magda Naeim, Nadia Ismiil, Valerie Dube, Guangming Han, Matthew Cesari, Fang-I Lu, Elzbieta Slodkowska, Sherine Salama, Hak Fai Chiu, Nim Li, Mahmoud Khalifa, Sharon Nofech-Mozes . Sunnybrook Health Sciences Centre, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada. Background: Distinguishing primary ovarian from metastatic carcinoma to the ovary is sometimes challenging to clinicians and pathologists and is important for selecting appropriate surgery, therapeutic options and prognostication. We re-examined the features traditionally used to assist pathologists in this differential diagnosis in a single, tertiary care practice.
Primary Versus Metastatic Ovarian Tumors: Challenging the Validity of Common Diagnostic Features

Design:
We reviewed the pathology of ovarian cancer specimens between 2000 and 2013, removed by at least a cystectomy procedure. Age, size, laterality, external surface involvement, CA-125 and past history were compared between primary ovarian serous carcinomas (OSC), non-serous carcinomas (NSC) and metastatic tumors (MT) to the ovary. c2 test, t-test and Mann-Whitney tests were used in the analyses. Results: After exclusion of cases with neoadjuvant chemotherapy, we identified 205 OSC, 161 NSC and 136 MT. In the MT group, 137 extra-ovarian sites of origin were identified, including colon (52, 38.2%), endometrium (31, 22.8%), appendix (13, 9.5 %), stomach (12, 8.8%), breast (11, 8.1%), cervix (6, 4.4%), upper GIT (4, 2.9%), lung (2, 1.5%) and other (6, 4.4%). The results are summarized in Table 1 . Compared with NSC, MT were significantly smaller (p = 0.002), more likely bilateral (p < 0.001) and showed external surface involvement (p < 0.001) but CA125 levels (p = 0.36) and age (P = 0.76) were comparable. Compared with OSC, MT had lower CA125 levels (p < 0.001). The difference in mean age, size, bilaterality and external surface involvement was not significant (p > 0.5). Table 1 OSCN=205 NSCN=161 MTN=136
Age (mean ± SD) 58.6 ± 12.9 56.6 ± 14.9 56 ± 12.1
Size (CM, mean ± SD) 11 ± 6.3 14.7 ± 7.9 11.8 ± 7.9
Bilaterality ( Background: The TLR4 pathway and the spindle assembly checkpoint have been implicated in numerous cancers including ovarian cancer. Two surrogate markers of these pathways, MyD88 and MAD2, have been extensively investigated by our group and have shown to have significant impact on patient prognosis including reduced PFS, OS and the development of chemoresistance to the front-line anticancer drug paclitaxel. The aim of this study was to assess whether these two potential prognostic biomarkers act via dependent or independent mechanisms. The relationship between MAD2 and MyD88 was investigated through alteration of MyD88/TLR4 expression in two ovarian cancer cells lines, a MyD88 negative cell line A2780 and a MyD88 positive cell line SKOV-3. Additionally two TLR4/MyD88 regulatory microRNAs Mir-146a and Mir-21 were also assessed in this study. Design: Alteration of TLR4/MyD88 expression in these two cell lines was achieved through the use of an MyD88 overexpression plasmid vector and through the use of siRNA targeting TLR4 or MyD88. Following transfection, MyD88, TLR4 and MAD2 expression was assessed through qPCR and western blot analysis. The expression of the two TLR4/MyD88 regulatory microRNAs, Mir-21 and Mir-146a was also assessed following confirmation of knockdown or overexpression. The effect on chemoresponse following knockdown of MyD88/TLR4 was also assessed in SKOV-3 cells using the CCK-8 assay.
Results: It was found that knockdown or overexpression of MyD88 in SKOV-3 or A2780 cells respectively had no effect on MAD2 expression or the expression of Mir-21 and Mir-146a. Additionally knockdown of TLR4 in both cell models was also shown to have no effect on MAD2. Interestingly, knockdown of TLR4 in SKOV-3 cells was shown to restore chemosensitivity to paclitaxel.
Conclusions:
The results of this study suggest that MAD2 and MyD88 are independent biomarkers in ovarian cancer. By using these two markers it may be possible to triage women into chemoresistant/chemosensitive groups prior to the onset of chemotherapy, with the ultimate aim of improving ovarian cancer patient prognosis.
High Grade Serous Carcinoma Arising in Low Grade Serous Carcinoma
Debra Bell, Sarah Jenkins, Yan Wang. Mayo Clinic, Rochester, MN. Background: Low and high grade ovarian serous carcinomas are now considered two distinct diseases with different clinicopathologic features and molecular alterations, and yet a small number of cases of high grade serous carcinoma arising in low grade serous carcinomas have been reported. The aim of this study was to examine the spectrum of atypia in a series of low grade serous carcinomas.
Design:
The slides from 246 serous carcinomas from the ovarian tumor repository were reviewed revealing 23 tumors with a low grade serous carcinoma component by the MD Anderson grading criteria. The histologic slides were examined for areas of nuclear pleomorphism greater than seen in low grade carcinoma but less than diagnostic of high grade carcinoma, foci that qualified as high grade serous carcinoma, and the mitotic rate. The clinicopathologic features and follow-up data were analyzed. Results: Of the 23 cases, 16 were pure low grade serous carcinomas, 3 were low grade with areas of increased nuclear pleomorphism, and four contained areas of high grade serous carcinoma. Conclusions: This study confirms the findings of others that low grade serous carcinomas are usually high stage at presentation, have a low mitotic rate and that a substantial number of patients will suffer recurrences or death from tumor over time. This study demonstrates that a spectrum of atypia exists in up to 30% of low grade serous carcinomas; focal "higher" grade nuclear pleomorphism may be present and some tumors may contain overt high grade serous carcinoma with a high mitotic rate. These latter tumors are similarly high stage with recurrences and death from disease. Extensive sampling of low grade serous carcinomas is warranted to detect these focally high grade tumors.
Prognosis of Ovarian Low Grade Serous Carcinoma: An Assessment of Multiple Grading Systems
Debra Bell, Sarah Jenkins, Janis Donovan, Yan Wang. Mayo Clinic, Rochester, MN. Background: It is now widely accepted that high and low grade ovarian serous carcinomas as defined in 2014 WHO Classification of Tumours of the Ovary and the two-tiered MD Anderson grading system are distinct disease entities with different clinicopathologic and molecular features. It is also widely assumed that low grade serous carcinomas have a better prognosis than high grade carcinomas, although several studies have questioned this conclusion. This study was undertaken to delineate the survival of low and high grade ovarian serous carcinomas utilizing all of the current grading systems in a large series of tumors treated at a single institution.
Design:
The slides of 346 of 990 patients entered in the Ovarian Cancer SPORE tumor repository with "serous" in the diagnosis field since 1990 were reviewed by two of the authors without survival information. 100 cases were deleted after histologic review because of borderline or mixed histology or the absence of slides from the files. The remaining cases were assessed for the following histologic parameters: two-tiered MD Anderson grade (WHO low or high grade), FIGO grade, Shimizu grade, original grade, mitotic rate. Survival was compared utilizing the Kaplan-Meier method along with logrank tests. Results: Utilizing the MD Anderson two-tiered grading system, 16 cases were pure low grade, seven cases with classic low grade carcinoma had high or higher grade foci (these 7 cases were eliminated from the statistical analysis of low vs high grade), and 223 were high grade throughout. Analysis revealed a difference in survival that approached statistical significance for both overall survival (p=0.079) and recurrencefree survival (p=0.087) using the MD Anderson two-tiered system. Dichotomizing the FIGO grade into low (FIGO 1) vs high (FIGO 2 and 3) revealed a trend toward a better recurrence-free survival (p=0.065), but no difference in overall survival (p=0.124). The other grading systems showed no differences in recurrence-free or overall survival.
Conclusions:
The two-tiered classification system reveals a trend towards better overall and recurrence-free survival among low grade cases that may become clearer as analysis of the remaining cases in the tumor repository increases the number of low grade carcinomas in the study. The presence of high grade carcinoma arising in low grade carcinomas warrants extensive sampling of low grade carcinomas to exclude a higher grade tumor.
Leiomyoma With Bizarre Nuclei: Correlation Between Morphology and Fumarate Hydratase/S-(2-Succino)-Cysteine Expression
Jennifer Bennett, Sarah Chiang, Ying-Bei Chen, Ann Bialik, Martin Aryee, Robert Young, Victor Reuter, Robert Soslow, Esther Oliva. Massachusetts General Hospital, Boston, MA; Lahey Hospital and Medical Center, Burlington, MA; Memorial Sloan Kettering Cancer Center, New York, NY. Background: Tumors associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome are characterized by cells with prominent eosinophilic nucleoli and perinucleolar halos. These features have also been observed in a subset of leiomyomas with bizarre nuclei (LMBN). While HLRCC is defined by germline mutations in fumarate hydratase (FH), resulting in formation of S-(2-succino)-cysteine (2SC), it is unknown if LMBN show a similar aberration. In this study, we evaluate LMBN morphology and its correlation with FH/2SC expression. Design: 28 LMBN were reviewed for cellularity (compared to adjacent myometrium), "alveolar pattern" of edema, staghorn vessels, distribution of bizarre nuclei, cytoplasmic hyaline globules, and eosinophilic nucleoli with perinucleolar halos. Immunohistochemistry for FH/2SC was performed. Data was analyzed by Fisher exact test with Bonferroni adjustment.
Results:
The patients ranged from 26 to 69 (mean 46.6) years and none had a history of renal or cutaneous tumors (unknown in 5). The morphologic features are highlighted in Table 1 . There was loss of FH staining with diffuse 2SC expression in 50% of cases. The presence of an alveolar pattern of edema showed a statistically significant association (p=0.0044) with aberrant FH/2SC expression. Weaker associations were detected for the presence of staghorn vessels, hyaline globules, and nucleoli/halos (p<0.05). Conclusions: Previously described morphologic features of HLRCC tumors and aberrant FH/2SC staining are not specific to this syndrome as both can be seen in an important subset of LMBN. For LMBN, the greater the number of associated morphologic features observed, the higher the likelihood FH/2SC will be aberrantly expressed (Table 2) . FH mutational analysis is in progress to further define FH negative LMBN. Background: Lynch Syndrome (LS) is defined by defects in one or more mismatch repair (MMR) proteins. Several morphologic features have been predictive of MMR loss in both LS-associated endometrial and colon carcinomas; however, no correlation has been identified for ovarian tumors. In this study we evaluate a series of ovarian clear cell carcinomas (O-CCC) to determine the incidence of MMR defects and potential association with specific histologic features. Design: 57 O-CCC were reviewed for predominant histological pattern (papillary, tubulocystic, solid, mixed), peritumoral lymphoid aggregates, inflammatory infiltrate, and nuclear pleomorphism. Immunohistochemistry for the 4 MMR proteins was performed and data was analyzed using the Fisher exact test. Results: Patients ranged from 31 to 82 (mean 55.6) years. Abnormal MMR expression was identified in 5% (3/57) of O-CCC and included MSH2/MSH6, MLH1/PMS2, and PMS2 loss. These patients were diagnosed at 31 to 40 (mean 37) years, were stage I (2) and stage III (1) at presentation, and none had a concurrent endometrial or colon carcinoma. Tumors with a diffuse inflammatory infiltrate and marked nuclear pleomorphism were more frequently associated with MMR defects (p=0.0041 and p=0.0455, respectively). All 3 O-CCC with MMR loss exhibited both features, but were found in only 7% (4/54) of tumors with MMR expression. The patient with loss of MSH2/MSH6 was confirmed to have a MSH2 germline mutation and testing is in progress for the others. Two patients (stage I and stage III) are alive without any evidence of LS-associated disease at 7 and 8 years, whereas the third was lost to follow-up.
Conclusions:
In this study, the frequency of abnormal MMR expression among unselected O-CCC patients was 5%, which although is slightly higher than LSassociated colorectal and endometrial carcinoma, is more striking given that O-CCC is much less common. Previous studies have been unable to identify a relationship between histology and MMR loss, but this study identified a correlation with a diffuse inflammatory infiltrate and marked nuclear pleomorphism. Potentially, O-CCC with these histologic characteristics can be selected for MMR analysis. Furthermore, given that stage III O-CCC typically has an unfavorable prognosis, perhaps association with LS potends a more favorable outcome.
Primary Extranodal Marginal Zone Lymphoma (MALT)-Like Lymphoid Proliferations of the Endometrium
Jennifer Bennett, Esther Oliva, Valentina Nardi, Neal Lindeman, Judith Ferry, Abner Louissaint. Massachusetts General Hospital, Boston, MA; Brigham & Women's Hospital, Boston, MA. Background: Primary lymphoma of the endometrium is exceptionally rare. Some recurring morphological and immunophenotypic features are described in case reports of low-grade endometrial B-cell lymphoma, but these have not been well characterized and their malignant potential is unknown. In this study, we define the morphological, immunohistochemical, and molecular spectrum of these atypical endometrial lymphoid proliferations. Design: 8 hysterectomies with a diagnosis of primary endometrial lymphoma/atypical lymphoid proliferation were identified from institutional archives. Histology was reviewed and lymphoid infiltrates were evaluated for expression of CD3, CD20, CD43, CD5, CD10, BCL2, CD21, CD23, kappa/lambda, IgG, IgM, IgD. FISH for IGH@ and MALT1 and PCR for clonal IGH@ gene rearrangements were performed. Results: Patients ranged from 50 to 87 (median 62) years. Lymphoid proliferations were primarily confined to the endometrium (6/8), nodular (7/8), and composed of a monomorphic population of small lymphocytes (8/8). In some cases, there was coalescence of nodules (3/8) or infiltration of myometrium (2/8). One case showed diffuse growth with extensive involvement of the endomyometrium, left ovary and fallopian tube, and regional lymph nodes. Pertinent immunophenotype and clonality results are shown in Table 1 . All cases were negative for IGH@ and MALT1 rearrangements by FISH. All patients with follow-up (6/8) are alive, and only one (with diffuse infiltrate) has persistent disease after resection alone (mean 3.3 years, range 4.1 months-8.7 years). Design: Formalin fixed paraffin embedded tissue from 12 ULM, 30 ALM, and 24 LMS was retrospectively collected and all cases were reviewed to confirm the diagnosis based on WHO and Stanford scheme. Six normal myometrium were used as control. Methylation analysis was performed using Sequenom MassArray. DNA from each case was extracted with QIAamp EpiTect Bisulfite kits and PCR amplification incorporating the T7 promoter sequence was performed and separated based on methylated versus nonmethylated CpG sites. Data was analyzed using Mass Spectrometry and biostatistical analysis was performed. EpiTect Control DNA and Control DNA Set were used as control DNA.
Results: DLEC1 and KLF11 were highly methylated in ULM in comparison to normal myometrium (p<0.001) and to LMS (p<0.05). The levels of KLF11 promoter methylation in ALM and LMS were very low and were significantly different from ULM (p<0.001) and comparable to methylation levels in myometrium. Similar findings were observed for DLEC1 promoter methylation in ALM and LMS. In contrast, the levels of RUNX3 methylation in LMS and ALM were significantly higher than that of ULM and myometrium (P<0.05 and <0.01 respectively).
Conclusions:
Data from chip-based methylation analysis of smooth muscle tumor related genes, DLEC1, KLF11, and RUNX3, show ALM has similar methylation patterns to LMS which are significantly different from ULM. Findings provide another layer of evidence of molecular similarity between ALM and LMS and our study suggests that methylation analysis can be a valuable tool in tumor classification. Background: Papillary squamous cell carcinoma (PSCC) is a rare variant of cervical carcinoma that histologically resembles transitional cell carcinoma of the urinary bladder. PSCCs are considered clinically aggressive, despite limited literature that predates the chemoradiation regimens currently used to manage cervical cancer. Design: Twenty cases of PSCC were identified over a 10 year period. Clinicopathologic variables were abstracted. The H&E slides of all PSCCs including diagnostic biopsies and specimens obtained at radical hysterectomy (RH) were reviewed as well as a retrospective cohort of IB1 conventional squamous cell cervical cancers (cSCC). Twotailed T-test and McNemar's test were used to assess statistical significance. Results: All PSCCs displayed papillary architecture with either squamous (n=13) or squamotransitional (n=7) morphology and included FIGO IA1 (n=1), IB1 (n=6), IB2 (n= 4), IIA (n=2), IIB (n=3), IIIB (n=2) and IVB (n=2) disease. Mean patient age was 47 ± 12.2 years (range: 26 to 76 years). All but one woman with ≤IB1 disease were treated with surgery, whereas all patients with ≥IB2 disease received chemoradiation.
Histologic evaluation of RH specimens demonstrated that IB1 PSCCs (n=5) invaded less deeply into the cervical stroma and showed significantly less lymph-vascular invasion (LVI) than IB1 cSCCs (n=36), despite equivalent mean tumor diameters. Mean duration of follow up was 26 ± 25 months (range: 3 to 102 months). At last contact, 14 patients were alive without disease. Three patients (IIB and IIIB -non-compliant with therapy; IB2 -positive pelvic lymph nodes) were alive with residual disease. One patient with IB1 disease died of unknown causes. Both patients with IVB disease were lost to follow-up shortly after diagnosis.
Conclusions: PSCC appears to be associated with a good outcome following current standard of care, with stage-specific therapy. Given that PSCCs demonstrate less stromal and lymph-vascular invasion than stage and size-matched cSCCs, it may be possible to consider surgical management for a subset of women diagnosed with IB2 and/or IIA disease that would be otherwise triaged to chemoradiation on the basis of tumor size alone. 
Morphologic Changes in the Gynecologic Tract in Response To
is a Selective Progesterone Receptor
Modulator recently approved in Canada for treatment of symptomatic uterine leiomyomas and menorrhagia. Previous studies have described novel histological changes in the endometrium in response to UPA, called "progesterone receptor modulator-associated endometrial changes", or PAEC. However, there are no published data on the effects of UPA on other areas of the gynecologic tract. Design: We evaluated pathology specimens resulting from various surgeries in patients who had received UPA prior to surgery. This included myomectomies and hysterectomies +/-salpingo-oophorectomies. Cases were reviewed to identify novel histologic changes (including PAEC) in all tissue types. Results: A total of 60 patients had surgical procedures. No novel histologic changes were identified in leiomyomas or ovaries. Within the endometrial tissues, 22 (50%) patients had changes of PAEC (Table 1 ). In the Fallopian tubes, 12 patients (39%) showed foci of variable epithelial atypia. Architecturally, cells were crowded and stratified, with loss of polarity. Mild to marked nuclear atypia was seen, with multinucleation. Cilia were maintained. Immunohistochemical staining for p53 and Ki-67 were normal in these areas. Conclusions: UPA/Fibristal causes reproducible unique changes in both endometrium and within the Fallopian tube epithelium. Awareness of these changes is necessary to prevent over-diagnosis of endometrial hyperplasia and/or tubal intraepithelial neoplasia in these patients. Background: NuclearFOXO1 expression is absent in the majority of Grade I uterine endometrioid carcinomas (UEC) and complex atypical hyperplasia (CAH). FOXO1 is a transcription factor that regulates apoptosis, cell cycle and metabolism. Nuclear FOXO1 expression is present in secretory glands, but is absent in proliferative glands. Inactivation of PTEN causes loss of nuclear FOXO1 expression and it has been shown that progesterone regulates FOXO1 expression in the endometrium. The purpose of this study was to determine if progestin treatment of CAH/Grade 1 UEC results in increased nuclear expression. Design: 7 cases of CAH/Grade 1 UEC before and after treatment with progestin were identified from our files. Slides were reviewed and histological features confirmed. The cases were scored for intensity and percent of nuclear and cytoplasmic staining in glands and stroma of lesional and normal tissue. The intensity of staining was scored as weak (0), moderate (1) and strong (3). In addition, human endometrial cell lines RL95 and PTEN deleted Hec1A clone 16 were evaluated for nuclear expression of FOXO1 by Western blot before and after treatment with progestin. Results: 5/7 of the pretreatment lesions showed a range of staining in the glands (weak to moderate cytoplasmic) and the stroma (predominately nuclear). Of these cases only 2 showed expression in normal tissue with a similar staining pattern. After treatment a range of staining was also seen, but 3/5 cases lacked glandular staining and 4/5 had reduced stromal staining. Only 2 cases showed an increase in the stroma: one showed an increase in nuclear staining (10% to 20%) and in the other staining was confined to the cytoplasm. Finally, 2 cases that completely lacked staining in the pretreatment lesions did not have residual disease on post-treatment sampling. The treatment of cell lines with progesterone did not result in the expression of FOXO1 in the nucleus.
Conclusions:
Previous studies have shown a lack of FOXO1 expression in CAH/ Grade 1 UEC and we have shown that inactivation of PTEN results in loss of nuclear FOXO1 expression. In both primary human tissue samples and endometrial carcinoma cell lines progestin treatment did not result in increased epithelial nuclear or cytoplasmic expression of FOXO1. Although the number of cases examined was small the concordance with the in vitro studies strongly suggests that the regression of lesions in response to progestin does not involve FOXO1 expression in either the glands or the stroma. Ai-Ying Chuang, Robert Young, Melinda Lerwill. Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; Massachusetts General Hospital and Harvard Medical School, Boston, MA. Background: The recent literature on ductal carcinoma metastatic to the ovary is limited. We evaluated our experience with particular attention to morphologic features that overlap with those of primary ovarian tumors. Design: 106 cases were identified from routine hospital and consultation material. Clinical data was reviewed, and the following pathologic features were evaluated: size, laterality, growth patterns, and cytologic features.
Ductal Carcinoma of the Breast Metastatic To the Ovary
Results:
The median age of patients at the time of detection of ovarian metastasis was 47 years (range, 17-79) . The breast cancer was diagnosed before the ovarian metastasis in 94 cases (interval: 0.14 to 312 months, mean 54.3); the tumors were discovered synchronously in 6; and in 6 the breast cancer was discovered after identification of the ovarian metastasis (interval: 0.5-6 months, mean 2). The size of grossly recognizable tumors (64 cases) ranged from 0.6 to 23 cm (mean 8). Bilateral tumors were grossly identified in 46 cases. The sectioned surfaces were typically solid, with cysts in 13 cases that also had a solid component. Microscopic examination disclosed bilateral ovarian metastases in 63 cases, ovarian surface involvement in 37 and lymphatic invasion in 43. Multinodular growth was seen in 61 cases. Necrosis was seen in 36 cases. There was typically a heterogeneous microscopic appearance with 91% of the tumors having more than one pattern. Discrete nests were the predominant pattern in 53%, followed by diffuse growth (25%), glands and small acini (16%), papillae (2%), single cells (2%), and colloid pattern (1% Background: Lobular carcinoma has a greater propensity to present in the ovary, compared to ductal carcinoma, and poses a different spectrum of differential diagnosis. We reviewed our experience with metastatic lobular carcinoma to evaluate both clinical and pathologic issues that cause diagnostic difficulty. Design: 38 cases were identified from routine hospital and consultation material. Clinical data was reviewed, and the following pathologic features were evaluated: size, laterality, growth patterns, and cytologic features.
The median age of patients at the time of detection of ovarian metastasis was 51 years (39-91). A diagnosis of breast cancer was made before the ovarian tumor was discovered in 31 cases (0.8-211 months, mean 58); the tumors were discovered synchronously in 2 cases; and in 5 cases the breast cancer was not identified until after oophorectomy (2-59 months, mean 35). The tumors were grossly bilateral in 21 cases. The size of grossly recognizable tumors ranged from 0.5 to 18 cm (mean 5.9). The sectioned surfaces were typically solid, with cysts in only 1 case that also had a solid component. Microscopic examination disclosed bilateral ovarian metastases in 30 cases, ovarian surface involvement in 15 and lymphatic invasion in 9. Multinodular growth was seen in 26. Necrosis was present in 4, and in all of them it was limited (<5%). Diffuse growth of cells with little or no intervening stroma was the predominant pattern in 22 cases, delicate cords in 9, and single cells or small clusters in 7. Signet ring cells were present in 9 but accounted for ³10% of the tumor in only 3. Pleomorphic nuclei were present in 4 cases. 3 patients had coincidental surface epithelial neoplasia in the background, and 1 had a fibrothecoma. The primary neoplasm most closely mimicked was adult granulosa cell tumor because of similar diffuse growth and relatively uniform nuclei.
Conclusions:
In 13% of patients with ovarian involvement by lobular carcinoma, the primary breast cancer was identified only after recognition of the metastasis, a higher percentage than for ductal carcinoma (6%). Lobular carcinomas in the ovary are of slightly smaller size and show a narrower morphologic spectrum than metastatic ductal carcinomas. The growth pattern is distinct from that of primary surface epithelial neoplasia and lacks the characteristic patterns of sex cord stromal tumors in the differential. 
Clinical Utility of Sentinel Lymph Nodes in Endometrial Cancer
Results:
We reviewed 138 cases with 1153 nodes; 363 SLNs and 790 NSLNs, with procurement rates of 97% (Table 1) . Metastatic disease was detected in 13% of cases; 6% of SLNs contained tumor versus 3% of NSLNs (p<.05). There was no relationship between size of metastasis and histologic grade, DMI, or lymph-vascular invasion (LVI). 98% of patients had concordant results; the false negative cases were serous cancer and adenosarcoma. Endometrioid histology was the most common (86%), with a NPV of 100%. Grade 1 endometrioid cases with positive SLNs had significantly more LVI and DMI>50% (Table 2) . 14% of these patients with <50% DMI had positive SLNs (micrometastases), thus requiring further lymphadenectomy. Furthermore, 21% of patients with negative SLNs had DMI>50%. These patients underwent unncessary pelvic lymph node dissection after frozen section assessment. The CAP/ASCCP Lower Anogential Squamous Terminology Guidelines recommend the use of p16 immunopositivity to categorize borderline cases as LSIL or HSIL. However, the reported rates of p16 immunopositivity among LSIL cases have been heterogenous, ranging from 0% to 47%. Additionally, the definition of immunopositivity varies among these studies from full-thickness to focal staining with few studies defining positivity as full thickness. We set out to determine the performance of p16 in LSIL cases within our patient population; characterized by high rates of immunosuppression secondary to HIV or organ transplantation. Design: We identified retrospectively 26 cervical biopsies or loop electrosurgical excision procedures (LEEP) with a diagnosis of LSIL from 2011-2014, excluding condylomas. Of the 26, 17 had sufficient lesional tissue and immunostaining using CINtec® p16INK4a was subsequently performed. Positive staining was defined as full-thickness nuclear and cytoplasmic positivity and was evaluated by 2 pathologists blinded to the patient's clinical history. The patient's history of HSIL, clinical history and HPV positivity were additionally recorded. Results: 13 of 17 patients (76%) were immunocompromised (12 HIV positive, 1 heart transplant). All 17 patients were positive for high risk HPV DNA prior to biopsy. 10 of 17 cases (59%) showed full-thickness immunopositivity for p16. HSIL was present on concurrent (1 within 4 months) LEEP in 6 of 17 (35%). LSIL p16 immunopositivity had a positive correlation with immunosuppression (p-value = 0.0241), whereas LSIL p16 immunopositivity did not appear to correlate with concurrent HSIL diagnosis (p-value = 0.37). The sensitivity of p16 positivity for concurrent HSIL was 71.4% (29.3%-95.5%) and the specificity was 50% (18.9%-81.1%).
Conclusions:
In this patient population with high levels of immunocompromise mostly due to HIV, the p16 positivity rate in LSIL is quite high, even using a conservative definition for positivity. Moreover, there appears to be a significant correlation between p16 immunopositivity and the presence of immunosuppression. This finding merits further study in a larger number of patients to determine whether recommendations for p16 usage should be modified in certain patient populations and whether p16 expression in LSIL has any implications for future risk of developing cervical cancer and precancers. In the meantime, this finding supports the opinion that p16 should be used only in cases truly concerning for HSIL to avoid overtreatment. Results: On histologic review, 76% (26/34) of all cases had at least focal endometrioid morphology, including 68% of those initially diagnosed as pure ESC (17/25). 62% (21/34) had a least one histologic or IHC finding considered a discriminatory "endometrioid" feature (squamous metaplasia, background hyperplasia, PTEN or ARID1A or MMR loss). Mean body mass index (BMI) in the cohort was 30, and 80% (27/34) were overweight or obese. 78%(25/32) of patients were postmenopausal at diagnosis. 81% of the whole cohort had aberrant p53 staining, 48% showed PTEN loss (complete loss in 12 patients, focal in 3), 6% had ARID1A loss and 6% had MMR abnormalities. 13 of 15 (87%) patients with PTEN loss also had aberrant p53 staining. Conclusions: Clinical, histologic and immunohistochemical results suggest that ESC in younger women frequently demonstrates many features traditionally considered "endometrioid" in nature, suggesting that at least a proportion of these carcinomas may derive from an endometrioid tumor substrate. The strong association between the presence of PTEN loss and aberrant p53 staining on IHC in this cohort may signify a form of "tumor progression" with early PTEN loss, followed by a change to more markedly high grade "serous-like" morphology with acquisition of a p53 mutation. Sabrina Croce, Agnes Ribeiro, Celine Brulard, Jean-Christophe Noel, Frederic Amant, Mojgan Devouassoux-Shisheborah, Laurent Arnould, Gaetan MacGrogan, Frederic Chibon. Bergonie, Bordeaux, France; Erasme Hospital, Bruxelles, Belgium; University Hospital of Leuven, Leuven, Belgium; Hospital Croix Rousse, Lyon, France; JF Leclerc, Dijon, France. Background: The diagnosis and management of uterine smooth muscle tumors with uncertain malignant potential (STUMP) is challenging and genomic data of these lesions as well as of uterine smooth muscle lesions in general are limited. We tested the hypothesis that genomic profile determination by array-CGH could split STUMP in 2 groups: one with scarce chromosomal alterations akin to leiomyoma (LM) and one with high chromosomal instability akin to leiomyosarcoma (LMS). Design: Array-CGH analysis was conducted on 29 FFPE STUMPs. A group of 10 LM and 10 LMS served as controls. The Genomic Index (GI) was calculated for each profile as follows: GI=A²/C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes. Results: Mean age was 50 years (24 to 85). Follow-up ranged from 12 to 156 months (average 70 months).The LM group showed a flat genomic profile with no or only sporadic alterations and the LMS group a rearranged chromosome profile with numerous intrachromosomal breaks. STUMP genomic profiles showed scarce to many chromosomal alterations.
Genomic Profile Analysis of Uterine Smooth Muscle Tumors By Comparative Genomic Hybridization. A Useful Diagnostic Tool in Challenging Lesions
At first by comparing GI in LM and LMS a threshold of 10 was assessed. Then this threshold was applied to STUMP below which non-recurring STUMPs were found akin to LM and over which STUMPs with recurrences and unfavorable outcomes akin to LMS were recorded.
Conclusions:
Array-CGH analysis is an innovative diagnostic tool for problematic smooth muscle uterine lesions, complementary to the morphological evaluation approach. We provide an improved classification method for distinguishing malignant tumors from benign lesions within the category of STUMP, definitely in cases with equivocal morphological features. The discrepancy between "cytologic atypia" and favorable outcome raises the question on the intrinsic nature of this neoplasm: a benign variant of LM with ischemic-reactive changes of degenerative nature or potentially a precursor of leiomyosarcoma. The goal of this study was to investigate the genomic profile of these tumors. Design: We collected 24 FFPE LM-BN from our consultation practices. Genomic profiles were analyzed by Array-CGH (a-CGH), MED12 mutation status was also investigated. FH (IHC) was performed. Ten uterine LM and 10 LMS served as control.
Results:
In 20/24 LM-BN the a-CGH could be analyzed. According to genomic profiles tumors were separated into 4 groups. One group was characterized by FH (ch1q42) deletion(6/20; homozygous 4/6), one group by RB-1 (ch13q14) loss (9/20; homozygous 4/9), another by RB-1 and TP53(ch17p13) losses (3/20) and the last group showed no deletions and rare chromosomal alterations (2/20). All LM-BN but 2 (in group 4) showed moderate chromosomal instability, that differ from LM (very flat profile) and LMS (with high level of instability). TP53 losses were heterozygous, and all associated with RB-1 deletions. In 6 LM-BN the usual component was analyzed and showed the same genomic profile as seen in areas with BN with some additional chromosomal events in the BN component. PCR for MED12 was feasible in 18/20 cases and was only mutated in 1. FH IHC was concordant with genomic status in 18/20 tumors with preserved FH expression in normal or heterozygous cases and 2 showing heterozygous deletion and negative IHC suggesting a mutation or an epigenetic event in the non-deleted allele.
Other less frequent genomic events were deletions of MED4 (ch13q14) (10/20), CAMTA1 (ch1p36)(8/20), ARID1A (ch1p35) (7/20), PTEN (ch10q23) (2/20) genes. Conclusions: LM-BN is a heterogeneous group of tumors with distinct genomic profiles with loss of 13q, 17p, 1p and 1q being recurrent genomic events and MED12 mutations being rare. These findings differ from those reported in conventional LM and LMS. Dolors Cuevas, Maria Santacana, Ana Velasco, Marta Romero, Maria Ruiz, Sonia Gatius, Xavier Dolcet, Xavier Matias-Guiu . Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRB-Lleida, Lleida, Spain. Background: Solid tumors show intra-tumor heterogeneity, which may be a challenge for evaluating the role of drugs in targeted therapies, since abnormalities in target genes can be heterogeneously distributed among different subpopulations of an individual tumor. The extent and prevalence of intra-tumor heterogeneity has not been fully evaluated in uterine serous carcinoma (USC). Design: Three independent frozen samples were obtained from 12 different USC. These 36 samples were subjected to MLPA analysis for 106 different chromosomal loci using four different Multiple Ligation Probe Amplification (MLPA) kits from MRC Holland (SALSA MLPA KIT P171-A2 Gain-1, SALSA MLPA KIT P172-B1 Gain-2, SALSA MLPA KIT P173-A2 Gain-3 and SALSA MLPA KIT P294-A1 Tumour-loss), and assessed by capillary electrophoresis. Analysis of chromosomal gains and losses was performed in each sample. Comparative analysis of the three samples from each tumors was also performed. Results: Chromosomal losses were observed in 22 of the 36 samples (61%), while chromosomal gains were seen in 35 of the samples (97%). The genes most frequently lost were FGFR1 (33%), BIRC1/NAIP (33%), BIRC4 (23%) and ERBB4 (16%), and the most frequently gained were CCNE1 (55%), EV11 (44%), PIK3CA (41%), UCKL4 (41%), AURKA (36%), NTRK1 (33%) and PTPN1 (33%). Concordance in chromosomal gain and loses between the three samples of each tumor was seen in 31 of the 106 chromosomal loci (i.e. 29%), while there was discordance in 47 (44%) of them. Overall 6 of the 12 cases exhibited significant heterogeneity (more than 3 discordant genes). The most frequently heterogeneous abnormal genes were ERBB2 (33%), UCKL4 (33%), BIRC4 (25%), BCAS1 (25%), TERT (25%), BCL6 (25%), NTRK1 (25%), SMARCB1 (25%) and tp53 (25%).
Tumor heterogeneity in Uterine Serous Carcinoma assessed By Multiple Ligase Probe Amplification
Conclusions:
MLPA results show a high frequency of chromosomal gains and losses, confirming the frequent presence of chromosomal instability in USC. Significant heterogeneity was seen in 50% of the cases; sometimes involving genes which may be targeted by molecular therapy. , <10, 11-50, 51-75, >75) . The score (intensity x %) was used for final evaluation. A score of 8 was the cutoff value for analysis. In an order from largest to smallest significant variables, a predictive model was constructed and examined by receiver-operator-characteristics analysis to determine area-under-curve (AUC . ASC1 failed to show any predictive value in our analysis. Conclusions: 1-Adding novel antibodies such as GEM and transgelin to the routinely used panel of immunomarkers proved to have more predictive power to distinguish ESS from LMS when compared to the old panel. 2-Cases with positive expressions of ER/PR/CD10/caldesmon/trangelin are more likely to be LG-ESS than LG-LMS, which is a vital distinction for any pathologist to make due to the indolent course and hormone therapy for the former and the more aggressive behavior and radiation therapy for the later. 3-Stahmin1 expression could be a useful immunomarker in conjunction with morphology to differentiate LM from uterine sarcoma, especially the atypical LM which sometimes creates a major diagnostic challenge. In addition BRCA+ patients demonstrate higher frequency of STIC in fallopian tubes at the time of risk reducing salpingo-oophorectomies (RRSO). We have implemented the protocol since 2007 and were interested in determining the frequency of TIC in patients with surgical intervention for non-malignant gynecologic conditions. Design: The search was restricted to patients with salpingo-oophorectomies with or without hysterectomy. Specimens were selected from patients with clinical or radiologic findings of either an ovarian/pelvic cyst. In addition, clinically symptomatic patients with abnormal vaginal bleeding, prolapse or pelvic pain were also included. BRCA positive patient undergoing RRSO were excluded. Results: A total of 11 cases of incidental tubal neoplastic changes were identified between early 2007 and September 2014. Patients' age range 39-78 (mean ∼66.2). Two patients were with p53 signatures and 9 with TIC. Two of the nine were also associated with 0.2 cm and 0.3 cm invasive high grade serous carcinoma, in the submucosa. Lymphovascular invasion was not present. Eight of eleven had negative companion pelvic wash; remainder 3 did not have pelvic wash cytology. Incidental TIC and p53 signature were found in 2 patients due to preoperative findings of simple and complex endometrial hyperplasia, 2 -ovarian cysts, 1 -ovarian teratoma, 1-pelvic cyst/mass, 1-prolapse, 1-pelvic pain and 3-unknown.
The presence of STIC in BRCA positive asymptomatic patients is equated to an early detection of this lethal disease, and is due to methodical examination of the fimbria per SEE-FIM protocol following RRSO. Our results support that all fallopian tubes should be evaluated thoroughly, implementing SEE-FIM protocol, regardless of cancer risk. , are oncogenic drivers of cervical adenocarcinoma (cACA). However, a distinct subset of cACA arise independent of HPV infection. We employed CGP of 58 cACA to elucidate differences in genomic alterations (GA) and therapeutic targets between HPV-16 or HPV-18 positive, and HPV-16/18 negative tumors. Design: Hybridization captured libraries for 236 cancer-related genes and 19 genes commonly rearranged in cancer was applied to ≥ 50ng of DNA extracted from 58 cACA FFPE specimens (22 primary, 36 mets) and sequenced to high, uniform coverage. HPV-16 and HPV-18 viral sequences, but not other hrHPV subtypes, were assayed. GA, which include: base substitutions, small insertions/deletions, rearrangements, and copy number alterations, were determined and reported for these patient samples. Results: cACA were predominantly advanced stage (III/IV 77%, I/II 16%) despite varied histologic grade (G1 34%, G2 26%, G3 40%) in these young women (avg. 45.4y). 38/58 (65%) cACA had detectable HPV-16 (n=16) or HPV-18 (n=22) sequences, and 35% were HPV-16/18 negative (HPVN). 202 total GA were identified in the 58 cACA (3.48 GA per tumor) of which 111 clinically relevant GA (CRGA) (1.91 per tumor) involving 36 different genes with 51/58 (88%) of cACA featuring at least 1 CRGA. HPV-18 positive cases had the fewest GA (HPV-18 2.9; HPV-16 3.13; HPV-Neg 4.4) and CRGA per tumor (HPV-18 1.6; HPV-16 2.1; HPVNeg 2.2). HPV-16 tumors had a significantly higher rate of PIK3CA activating mutations compared to HPV-18 tumors (53% vs. 9%, p<0.01). HPV-16/18 negative tumors had higher rates of TP53 loss of function (55% vs. 8%, p<0.001), and CDKN2A/B loss and MYC amplification (each 20% vs. 0%, p=0.016) compared to HPV-16/18 positive tumors. Additional CRGA included AKT1 (5.3%), ERBB2 (15.8%) , GNAS (15.8%) , KRAS (19.3%), STK11 (17.5%), and RICTOR (12.3%) . One HPV-16 positive cACA with a late recurrence in the lung harbored an FGFR3-TACC3 gene fusion and showed a partial response to an FGFR3 inhibitor. Conclusions: Frequent CRGA characterize HPV-16/18 positive and negative cACA. HPV-16/18 positive subtype correlates with the mutational mechanism of signaling pathway activation, while tumor suppressor loss is common HPV-16/18 negative cACA. Novel targets were identified at a high frequency in both HPV-16/18-positive and negative cACA providing rationale for CGP-directed therapeutic decision-making. Background: Deregulation of CDK4/6, cyclin D/p16 and retinoblastoma (Rb) pathways are known aberrations in cancers. There has been a recent interest in exploring the combination of letrozole and CDK4/6 inhibitors in recurrent ER+ ovarian cancers. This study aimed to determine the frequency, patterns and clinicopathologic significance of Rb, p16 and ER in a large cohort of ovarian tumors (OVTs). Design: Expression of Rb, P16 and ER was assessed by IHC on a tissue microarray of 177 OVTs. Nuclear staining for Rb was scored: negative (neg), (1+) and (2+) positive. Strong and diffuse p16 was considered positive. The H-scoring (H) system was used to evaluate ER. For the purpose of analysis, Rb1+ and ER of H£25 were considered neg. Results: Table 1 summarizes the frequency of the markers in OVTs. Rb was neg in 100% GCTs (56% specificity p<0.001) and 79% of GCTs were neg for all 3 markers (85% specificity p<0.001). Co-expression of all three markers was 96% & 93% specific for HGSC and LGSC (15% and 13% sensitivity p<0.001). Rb was positive in 67% grade (G) 1/2 vs. 43% G3 tumors (p<0.05). P16 was positive in 31% G1/2 vs. 68% G3 tumors (p<0.001). There was no significant difference in the pattern of the markers with tumor size, lymph node and metastasis. ('undiff-conn') or differentiated ('diff-conn') conditioned media for 7 days. Differentiation status was confirmed by loss of expression of SSEA4 (flow cytometry) and Oct4-Sox2-Nanog (qPCR).
Results: Undifferentiated and differentiated cells were co-cultured in a 1:9 ratio, which arrested the growth of undifferentiated cells after only 7 days. 
Results:
The patients' ages ranged from 22 to 66 (mean: 30) years. All but three of the patients were premenopausal. Histologically, the lesions were composed of a biphasic proliferation of architecturally complex and cytologically atypical endometrial glands with a myomatous or myofibromatous stroma. Squamous metaplasia or morules were observed in 58 cases. Twenty-two had evidence of background endometrial hyperplasia and 17 had endometrioid carcinoma (14 in APA and 3 in the adjacent endometrium). All 6 patients who were initially treated with curettage or polypectomy followed by hormonal therapy had residual or recurrent APA. One treated by hormonal therapy became pregnant. Patients treated with hormonal therapy exhibited a decreased N/C ratio of epithelial cells, persistent atypical glandular structures, and a markedly edematous stroma. Hysterectomy was performed in 14 patients because a definite diagnosis could not be made preoperatively, the curettages raised the possibility of adenocarcinoma, or because there was a high possibility of residual or recurrent lesions. All showed residual or recurrent APA in hysterectomy specimens. Two showed superficial myometrial invasion, and three showed APA in a focus of adenomyosis. The overall residual or recurrent lesion rate was high (23 /70, 33%). All patients were alive and well at 1 to 202 months (mean, 39.6 months).
Conclusions:
The rate of recurrent or residual APA was high, and the effects of hormonal therapy were limited. The risk of endometrial carcinoma in women with APA is also high. This study suggests that APA should be carefully evaluated, and cannot be regarded as a completely benign entity. Representative sections from each case were cut and subjected to microdissection, either laser-assisted or with a needle under a stereo-microscope. DNA was extracted from each tumor component and matched normal tissue and subjected to massively parallel sequencing using the MSK-IMPACT platform that targets the coding regions of 341 actionable cancer-related genes. Somatic single nucleotide variants were detected by MuTect; insertions and deletions were detected by VarScan2 and Strelka; copy number alterations were defined using VarScan2. Private mutations in each component were confirmed by Sanger sequencing.
Results:
The 4 tumors were classified as mixed serous and high-grade endometrioid carcinoma, mixed serous and low-grade endometrioid carcinoma (SC/ELG), mixed low-and high-grade endometrioid carcinoma, and mixed high-grade endometrioid and undifferentiated carcinoma (EHG/U). In all cases, both components were found to be clonally related based on the presence of identical somatic genetic alterations. The number of mutations in common between the two components varied from case to case (median 10, range 1 to 217). A POLE hotspot mutation was found in both components of the SC/ELG, which showed an extraordinarily high number of somatic mutations, consistent with the ultramutator phenotype. In each case, morphologically distinct components harbored private genetic alterations (median 5, range 1 to 100), including mutations in TOP1, SMARCA4, PDL1 and JAK3.
Conclusions:
The histologically distinct components of MECs are composed of distinct clonal populations of neoplastic cells sharing the same initiating genetic lesions (i.e. founder somatic mutations), however each component displays private genetic events.
Our findings have potential therapeutic implications, as mutations affecting targetable cancer genes may vary according to the histologic component of MECs.
Stathmin-1 Distinguishes High-Grade From Low-Grade Cervical Intraepithelial Neoplasm
is an important cytoplasmic microtubuledestabilizing protein and has been reported to be diagnostically useful in identifying cervical high grade squamous intraepithelial lesion (HGSIL). The objective of this study is to establish the diagnositc threshold of STMN by stratifying the staining grade at different layers, and to determine the sensitivity, specificity, and positive predictive value of STMN in cervical dysplasia by comparing to p16. Design: Cervical biopsy specimens (including 28 cases of low grade squamous intraepithelial lesion (LGSIL/CIN1), 55 cases of HGSIL (CIN2 and CIN3), and 5 benign cases) were selected for STMN and p16 immunohistochemical staining. At least two independent blinded reviews were performed for each biopsy. For STMN, the staining is evaluated as either negative (no staining above the basal layer) or positive (cytoplasmic staining above basal layer). Further grading system for STMN above the basal layer is delineated as 0 (< 5%), 1 (5-25%), 2 (26-75%), and 3 (>75%) at different layers. Of p16 staining, only band like nuclear staining of p16 is considered positive. Sensitivity (SS), specificity (SP), and positive predictive value (PPV) are calculated. Conclusions: Cytoplasmic staining of STMN above basal layer in cervical mucosa is a highly specific marker for HGSIL. By combining with p16, STMN can increase the specificity and sensitivity for CIN2, and could be used to distinguish from LGSIL and reactive/metaplastic cervical lesions. It might be interesting to set up a large study to follow up cervical lesions for their risk levels by combining histological diagnosis and biomarkers including STMN and p16.
Fibroepithelial Polyps of the Vagina -A Clinical and Pathologic Study of 70 Cases
Maria Gabriela Gasparinho, Marco Ferreira, Antonio Alves, Rita Luis. Hospital CUF Descobertas, Lisboa, Portugal; Centro Hospitalar Lisboa Norte, Lisboa, Portugal. Background: Fibroepithelial polyps of the vagina are relatively common lesions. However, their morphologic spectrum, although described in previous reports, has not been yet clearly characterized in a large series. Our objective was to assess the clinical and pathologic features of a series of vaginal fibroepithelial polyps. Design: Pathology Department databases were reviewed from 2003 to 2013. Slides of vaginal fibroepithelial polyps were examined. Size, stromal hypercellularity, multinucleation, cytological atypia, mitosis and associated epithelial changes were recorded. Clinical charts were consulted, recording patients' age, fertile status and associated gynecological pathology. Twenty cases of normal vaginal samples were used as controls. Statistical analysis was performed with GraphPad Prism® software.
Results:
We identified 70 cases of vaginal fibroepithelial polyps, corresponding to 65 patients (mean age: 54,8 years; range: 12-85 years). Four patients had multiple polyps, no patient was pregnant and 3 patients had previous radiation therapy for cervical or vulvar neoplasia. Thirty-six patients (51,4%) were post-menopausal. Fibroepithelial polyps had a mean size of 13,03 mm (range: 2-45 mm). Stromal hypercellularity (70% of cases) and stromal cellular multinucleation (92,9%) were significantly different between cases and controls (p<0,0001); all polyps larger than 12,5 mm were hypercellular and displayed multinucleated cells (p<0,01). Stromal cellular atypia was noted in 5,7% of cases; there was a tendency of atypical polyps to be larger than non-atypical (20,5 mm +-6,1 vs 13,8 mm +-9,8, p=0,07). Several kinds of stromal general features were noted, mainly: angiomatoid (24,3%), fibrotic (24,3%) and myxoid (5,7%). No mitotic figures were found in stromal cells. Epithelial changes were noted, such as acanthosis, papillomatosis and reactive changes (38,6%), but no conclusive evidence of HPVcytopathic change was observed. Conclusions: Stromal hypercellularity and multinucleation are common features in vaginal fibroepithelial polyps and are related with the size of the polyp. Stromal cell atypia, despite of being an unusual finding, has a tendency to be also related with the size of the polyp. Epithelial reactive changes are frequent but nonspecific features.
Fimbria and Ampulla Tubal Epithelium Have Similar Transcriptome Profiles
Sophia George, Anca Milea, Noor Salman, Patricia Shaw. University Health Network, Toronto, Canada. Background: Recently described precursors of High Grade Serous Carcinoma, the p53 signature, a latent precursor, and Serous Tubal Intraepithelial Carcinoma, a premalignant precursor, occur most frequently at the distal and fimbriated end of the fallopian tube (FTE). We recently demonstrated that the FTE of BRCA1 mutation carriers, at genetic risk of HGSC, have altered signaling pathways compared to controls. A key question is whether the gene expression differences identified at the ampulla between BRCA1 and non-mutation carriers is similar to differences at the fimbria. This study determines the transcriptome profiles of normal fimbrial FTE and normal ampulla FTE which may lead to an understanding of why the distal end of the fallopian tube is preferentially predisposed to malignant transformation. Design: Snap-frozen matched fimbria and ampulla tissues were controlled for age and ovarian cycle status at surgery. Cases included 12 luteal phase and 12 follicular phase women at no known risk for ovarian cancer. Laser capture microscopy was used to microdissect FTE cells, using 7-10 sections per case. Total RNA was isolated, RNA extracted and cDNA amplified. The expression profiles were generated using Affymetrix Human Genome HTA-2.0 Array.
Results: Using gene level differential expression analysis with Affymetrix Expression
Console software, we performed unsupervised hierarchical clustering analysis with all 24 samples. We used a fold change of < -2 or > 2 and ANOVA p-value < 0.05 as a cut-off criteria for selecting genes. The cases clustered predominantly by ovarian cycle status rather than by their differences in anatomical origin or their matched pair. There were 427 genes differentially expressed amongst the 4 groups -Fim-Luteal, Fim-Follicular, Amp-Luteal and Amp-Follicular. Independent of ovarian cycle status, very few differences (35 genes -SALL1, SERPINA3, ANXA13, PDK4, ME1, GSTA1, GSTA2 -genes involved in metabolic pathways) were observed between the ampulla and fimbria FTE.
Conclusions:
The epithelia of the anatomically high-risk fallopian tube -the fimbria, show few differences in gene expression profiles compared to the lower risk portion -the ampulla. Expression differences predominantly are in response to the hormonal mileu, i.e. the secretory and proliferative phases of the ovarian cycle. The increased anatomic risk of the fimbria is likely due to effects of the microenvironment, such as repeated exposure to follicular fluid at ovulation, rather than intrinsic differences of the FTE in the two sites.
Next Generation Sequencing for High Grade Neuroendocrine Carcinomas of the Cervix
Ryan Gertz, Russell Broaddus. University of Texas MD Anderson Cancer Center, Houston, TX. Background: Cervical neuroendocrine carcinoma is a rare but aggressive malignancy with limited data regarding its molecular genetics. Identification of clinically actionable mutations in this tumor type may help to direct targeted therapies. The purpose of this study was to compare the molecular changes in neuroendocrine carcinoma of the cervix to those of the more conventional cervical carcinoma histologies, squamous cell carcinoma and adenocarcinoma. Design: We retrospectively analyzed next generation sequencing data based on a 46/50 gene platform consisting of mutational hotspots in a series of patients with advanced stage cervical carcinoma from 2012-2014. The formalin-fixed, paraffin-embedded tissue from 52 tumors, 17 neuroendocrine carcinomas and 35 squamous cell carcinomas/ adenocarcinomas (conventional histology), was analyzed. Results: Nine/17 (53%) of the neuroendocrine carcinomas and 20/35 (57%) of the conventional histology carcinomas demonstrated at least one mutation from the panel.
Among the neuroendocrine carcinomas, mutations were identified in TP53 (4/17, 24%), KRAS (3/17, 18%), PIK3CA (1/17, 6%) and GNAS mutation (1/17, 6%). For the conventional histology tumors, mutations were identified in TP53 (2/35, 6%), KRAS (4/35, 11%), PIK3CA (7/35, 20%) and GNAS mutation (3/35, 9%). Conclusions: Mutation in PIK3CA has been previously identified to be a relatively common and targetable aberration in cervical carcinomas with conventional histologies. However, high grade neuroendocrine carcinomas only rarely have mutation in PIK3CA. The mutation pattern found in small cell lung carcinomas is distinct from that seen in the neuroendocrine carcinomas of the cervix, suggesting that they may require a different treatment strategy. For example, small cell carcinoma of the lung frequently has RB1 mutation; this was not observed in our patient cohort. Given the paucity of mutations identified in clinically actionable genes, patients with high grade neuroendocrine carcinomas should be considered for more extensive molecular diagnostics testing platforms.
Specific Patterns of Invasion in Endometrial Carcinoma Are Associated With Isolated Carcinoma Cells in Lymph Nodes
Nadia Giannakopoulos, Eric Konnick, Florencia Jalikis, Mara Rendi, Rochelle Garcia. University of Washington, Seattle, WA.
Background:
The most important factor in determining prognosis in endometrial carcinoma is the presence of metastasis, including lymph node (LN) metastasis. Previous work has demonstrated that the presence of microcystic, elongated and fragmented glands (MELF) and single cell/cell-cluster invasion (SCI) is predictive of LN metastasis in low stage/well-differentiated endometrial carcinoma. One study commented on the presence of subtle lymph node metastasis in cases with MELF; indeed, we have observed that cases with MELF/SCI often have occult LN metastasis present as single carcinoma cells in sub-capsular sinuses or scattered in the LN. We undertook a retrospective review of endometrial carcinoma cases to determine whether the presence of MELF or SCI predicts the presence of occult LN metastasis.
Design: 82 cases of endometrioid endometrial carcinoma with pelvic and/or para aortic LN metastasis were reviewed and scored for presence or absence of MELF and SCI along with standard grading and staging parameters. LN metastasis were classified by nodal group (pelvic or para aortic) and categorized into three categories: isolated carcinoma cells (ICC), defined as isolated cells scattered throughout the node or forming a cluster <0.05 cm, micrometastasis (0.05-0.2 cm) or macrometastasis (> 0.2 cm). Comparisons were made between cases with MELF and/or SCI patterns and presence of ICC, micrometastasis, and macrometastasis in pelvic and para aortic nodes using chi squared analysis. Results: In our cohort, 45% of cases had both MELF and SCI, 3.7% had MELF alone, 15.9% had SCI alone and 35.4% of cases had neither. There is a statistically significant association between the presence of MELF, SCI or both and the presence of ICC in the pelvic and/or para-aortic lymph nodes (p<0.005 for all comparisons). Background: Diagnosis of dVIN is one of the greatest challenges in gynecologic pathology. We have previously shown that staining for CK17 can highlight the cells of dVIN, with positive staining of lesional cells and absence of staining in adjacent benign epithelium. We sought to validate this finding in an independent set of cases. Design: 28 cases of dVIN were identified and a single representative block chosen for immunostaining. CK17 and p53 immunostaining was performed in each case. CK17 staining was assessed based on distribution (focal versus diffuse) and intensity (weak, moderate or strong), while p53 immunostaining was recorded as abnormal (either complete absence of staining, or stronger nuclear staining of significantly more basal squamous cells that was present in adjacent benign/reactive squamous epithelium) or normal (weak to moderately intense staining of some basal cells, similar to what was present in benign squamous epithelium). Results: CK17 positivity was seen in 26 of 28 (93 %) cases of dVIN. In 24 cases CK17 immunoreactivity was strong and diffuse, while in 2 cases the staining was more focal and of intermediate to strong intensity. The transition from neoplastic to non-neoplastic epithelium was marked by an abrupt change from immunoreactivity to negative CK17 staining. p53 staining could be evaluated in 26 cases and was abnormal in 21 (complete loss of p53 staining in 10 cases and more intense p53 immunoreactivity in 11 cases). Conclusions: CK17 immunostaining can serve as adjunct in the diagnosis of dVIN, or in helping to assess extent of disease by recognizing the boundary between the neoplastic and benign squamous epithelium. Background: Germline mutations in BRCA1/BRCA2 are associated with a markedly increased risk of developing tubo-ovarian cancer. Most cancers seen in these patients are known to be high-grade serous carcinomas, but a detailed assessment of cancer histotypes in these patients, based on modern diagnostic criteria, has not been done. Design: 117 cases of tubo-ovarian cancer were identified in patients with known germline BRCA1 or BRCA2 mutations, and all slides from these tumors were reviewed by a gynecological pathologist. Results: Of 117 tumors, 106 (91%) were high-grade serous carcinomas. The non-highgrade serous carcinomas included 4 low-grade serous carcinomas, one with admixed serous borderline tumor, 1 serous borderline tumor, 2 endometrioid carcinomas (one of fallopian tube origin and one arising in an endometriotic cyst), 2 clear cell carcinomas, 1 carcinosarcoma, and 1 dysgerminoma. All cases of low-grade serous carcinoma and endometrioid carcinoma tested to date showed "wild-type" p53 expression pattern. Further molecular analyses are in progress. Conclusions: : A large majority of tubo-ovarian cancers arising in patients with BRCA1 or BRCA2 germline mutations are high-grade serous carcinomas, but a range of other cancer histotypes are occasionally encountered. Although some non high-grade serous cases may be coincidental, and unrelated to the underlying BRCA1 or BRCA2 mutation, there does appear to be an increased risk of low-grade serous carcinoma in these patients.
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Meconium-Associated Vascular Necrosis Is a Significant Placental Lesion Underdiagnosed By General Surgical Pathologists
Amanda Gohlke, Joseph Jakowski, Ema Dragoescu. Virginia Commonwealth University, Richmond, VA.
Background:
The clinical utility of placental examination is to help explain adverse pregnancy outcomes. The general surgical pathologists (GSP) often perform this exam; however, studies have shown that they do not always recognize clinically important placental lesions that lead to poor outcomes. One such lesion is meconium-associated vascular necrosis (MAVN) that we had observed at our institution to have a very low diagnostic rate (<0.1%) compared to that reported in the literature (0.9-1.7%). The current study investigates this underdiagnosis and aims to identify the most useful histological criteria for the diagnosis. Design: A 4-year retrospective review of all placentas with meconium was undertaken after identification from a computerized database using the key words "meconium" or "green." Two independent GSP were blinded to the clinical history and original diagnoses and a histologic exam of the umbilical cord for MAVN was performed. The critera included 1) rounding of the peripheral smooth muscle cells, 2) eosinophilic cytoplasm, 3) condensation and fragmentation of the nuclei, and 4) discohesion of the smooth muscle cells in the absence of inflammation. Cases were classified as "yes", "maybe", or "no" for MAVN. All cases classified as "yes" and "maybe" were re-reviewed by all the authors for a consensus diagnosis. The maternal and fetal history was reviewed for all these new MAVN cases.
Results: 313 placentas with meconium were found. 3 cases of MAVN previously identified were excluded. One GSP identified 5 cases as "yes" and 19 cases as "maybe" and the second GSP identified 7 cases as "yes" and 9 cases as "maybe". The GSP results were concordant for "yes" in 4 cases and as "maybe" in 3 cases. Consensus review finally classified 19 cases as MAVN with 68.4% associated with intrauterine fetal demise (IUFD). In the remaining cases, birth history indicated good outcomes. The most useful diagnostic feature was the presence of bright eosinophilic cytoplasm, visible at lower magnification, to aid in distinction from histologic mimics. Conclusions: MAVN is underdiagnosed by the GSP and it is a significant lesion strongly associated with IUFD. With education and adherence to criteria, we were able to identify a significant number of new MAVN cases in retrospective review.
Microcystic, Elongated, and Fragmented (MELF) Pattern Invasion in Ovarian Endometrioid Adenocarcinoma Allison Goldberg, Daniel De Cotiis, Joanna Chan. Thomas Jefferson University
Hospital, Philadelphia, PA; Temple University, Philadelphia, PA. Background: Microcystic, elongated, and fragmented (MELF) is a well-recognized pattern of uterine endometrioid carcinoma (UEC), known to be associated with lymphovascular space invasion and occult lymph node metastasis. Currently, there is no literature evaluating MELF in ovarian endometrioid carcinoma (OEC) and its possible pathologic associations or prognostic implications. In this study, we retrospectively evaluated cases of OEC for MELF, associated pathologic features, and associated surgical staging information. Design: Forty consecutive cases of OEC without concurrent UEC from our institution (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were reviewed by two pathologists for MELF, histologic subtype, tumor grade, incidence of bilateral disease, presence of lymphovascular invasion, evidence of extranodal metastasis at surgical staging, and presence of lymph node metastasis. Data were analyzed using the Barnard exact test analysis. Results: MELF pattern invasion, see figure 1, is identified in 28% of the cases reviewed. No cases show concurrent endometriosis or lymphovascular invasion, compared to OEC without MELF pattern invasion, of which 24% show endometriosis (p= 0.002) and 17% show lymphovascular invasion (p= 0.014). In patients with complete pelvic staging, pelvic lymph node metastasis is in 50% of patients with MELF invasion compared to 17% of patients without MELF. No association between MELF pattern invasion and bilaterality of disease, extranodal metastasis, or high grade features, such as clear cell, mucinous, or serous is found.
MELF Invasion in Ovary
Conclusions: MELF occurs in OEC at a similar or higher frequency than in UEC. MELF should be kept in mind when assessing OEC, as the pattern may be confused with endometriosis or endosalpingiosis. Although MELF is not associated with endometriosis or lymphovascular invasion, it is associated with positive lymph nodes in patients with full pelvic staging. This suggests the possibility that MELF tumors are under-sampled, and should prompt further evaluation.
Further studies of MELF will focus on immunohistochemical and molecular markers, as well as clinical outcomes associated with MELF in OEC.
Differential Expression Patterns of GATA-3 in Usual and Differentiated Types of Vulvar Intraepithelial Neoplasia: Potential Diagnostic Implications
Abha Goyal, Bin Yang. Cleveland Clinic, Cleveland, OH. Background: The two types of high-grade vulvar intraepithelial neoplasia (VIN), usual and differentiated types, have distinctive etiology, pathogenesis, and natural history. Little is known regarding the expression of GATA binding protein 3 (GATA-3) in VIN. The aim of this study was to determine whether these two types of VIN show any differences in the expression of GATA-3. Design: Thirty-three cases of differentiated VIN were retrieved from archives. 15 of these were associated with invasive squamous cell carcinoma. 29 cases of usual type VIN and 20 cases of lichen sclerosus (with no prior history of VIN or carcinoma) were also obtained. Immunohistochemical staining for GATA-3 was performed on representative sections. Nuclear staining was considered positive. Staining patterns were recorded in terms of: intensity as weak (1+), moderate (2+) or strong (3+), percentage of cells as 0-25%, 26-50%, 51-75%, >75% and pattern of epithelial distribution.
Results:
The benign non-neoplastic epidermis (identifiable in 45 cases) showed strong (3+) and diffuse (>75%) GATA-3 staining from basal to spinous layer. All cases of usual type VIN (28/28, 100%) and of lichen sclerosus (20/20, 100%) had a staining pattern identical to the benign epidermis. The pattern of GATA-3 expression was distinct in differentiated type VIN. Partial or complete loss of GATA-3 expression was seen in the basal cell layer of the neoplastic epithelium in 29/33 cases (88%) -> 75% basal cells with 0-1+ staining in 25 cases, 26-50% basal cells with 0-1+ staining in 4 cases. 15 of these were accompanied with to 0 to 1+ staining of the parabasal cells, 2 cases showed loss of GATA-3 in the spinous layer as well. The remaining 4 (12%) cases revealed intact GATA-3 expression similar to the benign epidermis. All invasive carcinomas (15/15, 100%) associated with differentiated VIN showed loss of GATA-3 expression -loss in > 75% tumor cells in 12/15 (80%) cases, loss in 26-50% tumor cells in 3/15 (20%) cases.
Conclusions:
Our study provides new insight into the pathways of development of the two types of VIN. Down-regulation of GATA3 appears to be associated with differentiated VIN and not with usual type VIN. The progressive loss of GATA-3 from differentiated VIN to invasive carcinoma indicates that the down-regulation of GATA-3 occurs in the early stage of vulvar carcinogenesis. The pattern of GATA-3 expression in differentiated VIN is distinct from the non-neoplastic epidermis and that of usual type VIN and can serve as a useful tool in facilitating its diagnosis.
GATA-3 Expression in Ovarian Tumors
Joseph Hatem, Carolina Reyes. University of Pennsylvania, Philadelphia, PA. Background: There are few studies that have looked at GATA-3 expression in ovarian tumors. This study evaluates the GATA-3 expression in a varied panel of ovarian tumors. Design: GATA-3 expression was evaluated by immunohistochemistry in 40 ovarian tumors on full tissue sections. Benign, borderline, and malignant neoplasms were all included in the analysis. GATA-3 expression was assessed as focal vs. diffuse and staining intensity was scored on a 0 to 3+ scale. Results: Of the 40 tumors, the majority were high grade serous carcinomas (22 cases), in addition, there were 4 endometrioid, 2 clear cell, 2 mucinous, 1 mixed clear cell and mucinous, 1 low grade serous, and 2 high grade carcinomas, unclassified. There were 5 borderline tumors and 1 Brenner tumor. Of the 40 neoplasms, 12 demonstrated at least 1+ focal GATA-3 reactivity by immunohistochemistry (30%). These included 8 high grade serous carcinomas, 1 endometrioid carcinoma, 1 clear cell carcinoma, 1 high grade carcinoma, and 1 Brenner tumor. Only 2 neoplasms demonstrated diffuse and intense (3+) staining for GATA-3 (5%). Conclusions: Strong GATA-3 expression is seen in a minority of ovarian neoplasms. The findings support prior studies and suggest that GATA-3 may be a useful marker in the setting of high grade tumors, especially in two clinical scenarios: within the estrogen receptor positive (ER+) tumor group for determining carcinomas of breast vs. Mullerian origin, and in distinguishing high grade gynecological vs. urothelial neoplasms.
Nuclear Localization of β-Catenin Highlights EMT-Like Changes in Aggressive Cases of Vulvar Squamous Cell Carcinoma
Emily Holthoff, Susanne Jeffus, Thomas Kelly, Steven Post, Charles Quick. University of Arkansas for Medical Sciences, Little Rock, AR. Background: β-catenin is an mediator of cell-cell interactions and adhesion in epithelium. Dysregulation of β-catenin signaling enables this protein to alternatively function as a nuclear transcription activator resulting in loss of cell adhesion, increased cellular proliferation, and phenotypic changes. Collectively, these changes characterize the epithelial-mesenchymal transition (EMT), which is associated with tumor progression in a number of malignancies. Vulvar squamous cell carcinoma (vSCC) is an understudied and highly morbid gynecologic malignancy. Studies have shown that vSCC with an infiltrative pattern of invasion is associated with worse outcomes, namely recurrence and lymph node metastasis, compared to those with nested/pushing patterns of invasion. We propose that infiltrative vulvar carcinoma may acquire increased aggressiveness through EMT-like changes reflected by aberrant nuclear localization of β-catenin. Design: Immunohistochemical staining patterns of β-catenin were analyzed in 30 cases of vSCC. Ten cases contained a purely infiltrative pattern of invasion, 10 displayed a purely nested/pushing pattern and 10 displayed a mixed pattern with components of both infiltrative and nested/pushing invasion. Stained tumor sections were analyzed for nuclear localization or membranous staining of β-catenin. A staining pattern was defined as predominant when present in >75% of tumor cells. Results: Predominant nuclear localization of β-catenin in tumor cells was observed in 8 (80%) tumors with a purely infiltrative pattern of invasion, compared to 3 (30%) in the purely pushing/nested tumors. In contrast, membranous staining for β-catenin predominated in 5 (50%) of the purely nested/pushing tumors compared to 1 (10%) of the purely infiltrative tumors. Both membranous staining and nuclear localization of β-catenin was observed in 7 (70%) of the tumors with mixed invasive patterns. Importantly, in 6 of these 7 mixed tumors (85%), β-catenin showed membranous staining in the pushing regions and nuclear localization in the infiltrative regions.
Conclusions:
Our results show that nuclear localization of β-catenin is highly associated with an infiltrative pattern of invasion in vSCC, suggesting that EMT-like changes may drive the more aggressive behavior in this subset of tumors. The application of β-catenin to the evaluation of vSCC can help to identify a subset of tumors with a greater propensity for recurrence and nodal metastasis, and therefore could lead to more precise treatment planning and use of adjuvant therapy. Results: Histologically, most cases formed exophytic papillary lesions (81%), but a few cases showed flat topped plaque with downward epithelial proliferation (19%). The cells were composed of variable proportion of basaloid and squamoid cells in all cases, and all contained variable amount of mucin secreting epithelium within the lesion. 52% showed localized koilocytosis. Seven were associated with HSIL; two in the previous conization, and five in the adjacent mucosa. P16 immunostaining showed non-block positivity in all cases, except in the associated HSIL. They were associated with HPV 6 (n=3), 11 (n=7), 16 (n=1), 16/18 (n=1), but nine were HPV negative on HPV DNA chips, which were confirmed by PCR. All the cases showed basal or parabasal expression of CK17 (reserve cel marker) in contrast to uniform negativity in LSIL. 91 % showed top heavy expression pattern (91%) for CK 7 in contrast to the negativity (94%) in LSIL. Conclusions: PIM is basically derived from columnar cells having metaplastic potential in the squamocolumnar junction, which was differentiated into reserve cells, and then toward immature and mature squamous epithelium. In contrast, LSIL appears to be a cellular change occurring in mature squamous epithelium. Cellular proliferation of PIM could be induced by HPV infection of both low and high risk HPV, but it is not necessarily associated with concurrent HPV infection. Association of HSIL in adjacent mucosa of PIM in some cases suggested a potential to progress from PIM to HSIL. Results: A total of 148 cases were included in the study. PAX8 immunohistochemistry was positive in 65% (13/20) of usual type endocervical adenocarcinomas, in 83% (5/6) of endometrioid endocervical adenocarcinomas, 43% (3/7) of adenosquamous carcinomas, and only 6% (6/109) of squamous cell carcinomas. One clear cell carcinoma and one serous carcinoma case also showed PAX8 immunoreactivity, while one basosquamous carcinoma, one large cell neuroendocrine carcinoma and two botryoid rhabdomyosarcomas were negative for PAX8. In addition to tumor type, histologic grade may also affect PAX8 expression. PAX8 showed higher sensitivity for well and moderately differentiated adenocarcinomas (67% and 78%, respectively) than poorly differentiated adenocarcinomas (25%). Poorly differentiated squamous cell carcinoma on the other hand appeared more likely to express PAX8 (9%) than well and moderately differentiated squamous cell carcinomas (0% and 2%). Conclusions: PAX8 is expressed in over 60% of endocervical adenocarcinomas, a much lower rate compared with previously reported high sensitivity (over 90%) for other Mullerian -ovarian non-mucinous and endometrial -adenocarcinomas. PAX8 immunostain should be interpreted with caution in a metastatic lesion, when the possible primary sites include uterine cervix as a significant proportion of endocervical adenocarcinomas and vast majority of cervical squamous cell carcinomas lack immunoreactivity for this marker.
Cyclin D1 Overexpression as a Common Denominator for the Development of Uterine Leiomyosarcoma and Smooth Muscle Tumor of Uncertain Malignant Potential
Wei Hong, Serena Wong, Natalia Buza, Pei Hui. Yale University New Haven Hospital, New Haven, CT. Background: The pathogenesis of uterine leiomyosarcoma (LMS) is poorly understood. Smooth muscle tumor of uncertain malignant potential (STUMP) has been proposed as a possible precursor, as a result of its borderline malignant morphology and recent molecular data. We investigated cyclin D1 expression among other cell cycle regulators in uterine benign leiomyoma (LM), STUMP and LMS. Design: Cases with a diagnosis of STUMP or LMS during a 31-year period were retrieved from our departmental files. All H&E slides were reviewed and re-classified according to the current (2014) WHO criteria as LM, STUMP and LMS, followed by tissue microarray (TMA) construction. Clinical and follow-up data were collected. Immunostains for cyclin D1, p53 and p16 were performed on sections of the TMA. Results: A total of68 cases were included in this study: 10 LM, 12 STUMP and 46 LMS. Follow up was available for 55 cases (mean: 81 months, range: 1-359 months).
Patients with LM and STUMP presented at a younger age (mean: 39 and 41 years, respectively) compared with LMS (mean: 58 years). LM and STUMP showed no tumor recurrence while LMS had a 55% recurrence rate with a mean time to recurrence of 26 months (1-105 months). LM and STUMP had a lower mitotic rate compared with LMS (mean: 5, 6, and 19/10 high power field, respectively). Over 50% of STUMP and LMS stained positive for p53, p16 and cyclin D1, while all LM cases were negative for p53 and only 20% of LM showed positivity for p16 and cyclin D1. No significant difference was found between STUMP and LMS for the expression of these markers. Background: Some tumors express programmed death ligand 1 (PD-L1) which has the unique capacity to engage PD-1 on T cells and block anti-tumor immunity. In clinical trials, blockade of PD-1 signaling with therapeutic anti-PD-L1 or anti-PD-1 antibodies has produced durable clinical responses in patients with lung adenocarcinoma, renal cell carcinoma, and melanoma. Because PD-L1 is upregulated in many EBV+ and HHV8+ lymphomas, some have proposed that that viral-driven tumors are particularly adept at co-opting the PD-1 signaling axis for immune evasion. In this study, we applied this model to vulvar squamous cell carcinomas (SCC), many of which are HPV positive and all of which are extremely difficult to manage once nodal spread has occurred. The goal was to determine whether PD-L1 expression occurs in these tumors, in which case patients with these tumors could be potential candidates for immunotherapy. Design: Whole tissue sections from 50 vulvar SCCs (14 HPV+; 36 HPV-) were immunostained using a monoclonal antibody for PD-L1 (clone 405.9A11). Semiquantitative scoring was performed for intensity (0=negative, 1=weak, 2=moderate, 3=strong) and the percentage of tumors cell positive (0= <10%, 1=10-50%, and 2=>50%). For statistical analysis, cases with >50% positivity were considered "strong positive" cases and a fisher's exact test was used. Results: 12 SCC (24%; 5 HPV+, 7 HPV-) showed <10% positivity, 24 SCC (48%; 9 HPV+, 15 HPV-) showed 10-50% positivity, and 14 (28%; 0 HPV+, 14 HPV-) showed >50% positivity for PD-L1. There was a highly significant association between strong positive cases (>50% tumor cells expressing PD-L1) and HPV negative tumors (p=0.005). However, in all, 76% of all tumors showed ≥ 10% immunopositivity for PD-L1. Conclusions: This is the first study to show significant expression of PD-L1 -a potential therapeutic target-in vulvar SCC and suggests the majority of patients with this tumor could be rational candidates for a trial of anti-PD-L1 or anti-PD-1 immunotherapy. Because PD-L1 expression in vulvar SCC was inversely correlated with HPV status, HPV likely employs alternate mechanisms for immune evasion. follow-up outcome were analyzed. Clinical follow-up is defined as follows: Regression = negative follow-up (including negative high risk HPV), persistence = follow-up with high-risk HPV or LSIL, progression = follow-up with ASC-H or ≥HSIL. Results: In all, 120 LSIL cases were studied; 82.5% (n=99) were SCJ-while 17.5% (n=21) were SCJ+. In the SCJ-population, majority of cases were p16-(68.7%, n=68 Conclusions: Multi-viral HPV subtypes infection is common in HSIL & SqCa involving multiple anatomic sites. As many as 5 subtypes are found in one case; the vaginal lesion has subtypes found in both cervix and vulva. HPV 51 is found to be the next most frequent subtype after HPV 16. Viral load in recurrent lesion was higher than the initial VIN-3 when it recurred after 4 years. Gradual diminishing of viral load was observed from primary in-situ lesion to invasive carcinoma to metastatic site. Design: 13 cases of EC-POLE from 2 academic institutions were included in this study; the clinicopathologic features of which were recently reported (Modern Pathology; in press). IHC for PTEN, ARID1A, p53, p16, PR, PMS2 and MSH6 was performed and slides were reviewed by 2 gynecologic pathologists. Results: 8 cases were purely and ambiguously endometrioid carcinoma (EMC); 7/8 were FIGO grade III. 3 additional tumors demonstrated defining morphologic features of EMC, at least focally, but also showed components suggestive of mixed EMC & SC, while 2 more cases were difficult to subclassify (ambiguous). All EC-POLE showed loss of PTEN and/or ARID1A. PTEN and ARID1A loss was observed in 10/13 and 6/13 cases, respectively. Diffuse P53 overexpression was seen in 2/13 cases, while P16 overexpression was found in only 1 case. 9/13 tumors were positive for PR. PMS2 or MSH6 loss was seen in 1 and 5 cases, respectively. The immunoprofile of the morphologically "mixed" carcinomas and ambiguous tumors is illustrated below.
Conclusions: Our study shows that IHC may be a useful adjunct tool in histotyping EC-POLE. Although ECs-POLE are commonly high grade and frequently show morphologic ambiguity and components raising the possibility of SC, our IHC findings support the presence of endometrioid differentiation in every tumor. Furthermore, homogenously aberrant p53 immunoexpression may be occasionally seen in EC-POLE. As these tumors have favorable prognosis, it is important not to miscalssfiy EC-POLE as SC. Interestingly, ~1/2 of EC-POLE shows abnormal DNA mismatch repair protein expression; the mechanism of which is still unknown. The cell cycle marker p16 has been shown to be overexpressed in uterine leiomyosarcomas and theoretically useful for distinguishing between benign and malignant smooth muscle tumors. Its use is limited in routine practice because it has been noted to show variable expression in benign histological variants, specifically, leiomyoma with bizarre nuclei, a tumor that is difficult to distinguish from leiomyosarcoma. The expression of p16 in other benign variants, particularly those with problematic histological features, has seldom been studied. Design: p16 expression pattern in 35 benign uterine leiomyomas with infarct type necrosis were studied. Any staining in the nucleus and/or cytoplasm was considered positive. The extent of positive staining surrounding the infarct was classified as none, <33%, 33-66% and >66%. The extent of staining in areas away from the infarct was classified as none, scattered/isolated, <33%, 33-66% and >66%. Clinical and drug histories and follow-up were also obtained. Results: Age of patients was 23-55 years (median, 43.6), and presentations were menorrhagia, pain, mass, or combinations thereof. 25 were treated with hysterectomy and the remainder with myomectomy. Preoperative drugs (oral contraceptives/GnRH-a/ tranexamic acid) were prescribed in 18. One was pregnant. Tumor sizes ranged from 1.5-24 cm (mean, 7.8). All tumors had absent-to-mild atypia except for one case in which the atypia was mild-to-moderate. The mean mitotic count was 1.4/10HPFs (ranged 0-16). All had unequivocal infarct-type necrosis. The extent of p16 positivity in areas surrounding the infarct was 0 in 3 cases (8.6%); <33% in 25 cases (71.4%); 33-66% in 4 cases (11.4%) and >66% in 3 cases (8.6%). The extent of p16 positivity in areas away from the infarct was 0 in 4 cases (11.4%); scattered/isolated in 21 cases (60%); <33% in 8 cases (22.9%); 33-66% in 1 case (2.9%) and >66% in 1 case (2.9%). None of the patients, including those with tumors that showed >66% p16 positivity, developed recurrence after a mean follow-up of 41.4 months (range 1-126 ECMD and 8 serous carcinoma (SC) were selected for this study. Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue sections that were macrodissected to ensure greater than 80% of tumor cells in the selected region. PNA-PCR amplification of KRAS codons 12 and 13 was performed (RIH, RI), followed by sequencing using capillary electrophoresis. MSI status was evaluated using Promega's MSI Analysis System, which uses fluorescent multiplexed PCR followed by fragment length analysis to compare the sizing patterns of five mononucleotide repeat markers and two pentanucleotide repeat markers between tumor and matched normal DNA. , and 16 cases (3.4%) were reported as N1 or N2 (lymph node positive). 1.0% (n=4) of MELF-negative cases and 16.7% (n=12) of MELF-positive cases had positive lymph nodes, p<0.001. Conversely, MELF was significantly more frequent in node positive patients (n=12, 75%) than in node negative patients (n=60, 13.2%), p<0.001. LVI was also significantly associated with N1 or N2 node status, with 0.7% (n=3) of LVI-negative cases and 43.3% (n=13) of LVI-positive cases demonstrating positive lymph nodes, p<0.001. However, logistic regression models to describe the relationship between positive lymph node status and LVI and MELF could not be explored due to the small numbers (n=3 and n=4) in some of these groups.
Conclusions:
In a large single-institution cohort of consecutive FIGO1 EEC with lymph node dissections, MELF invasion patterns were noted 15.3% of the time and were significantly associated with positive lymph nodes. Despite the large number of cases in this series, the difficulty of studying node-positive FIGO1 EEC is highlighted, in that our multivariable model was not possible due to small n values in some of the groups. Further evaluation of MELF invasion patterns and their influence on LVI and lymph node metastases is warranted.
Dissecting Gonadoblastoma of Scully: A Morphologic Variant That Mimics Germinoma
Chia-Sui Kao, Muhammad Idrees, Robert Young, Thomas Ulbright. Massachusetts General Hospital and Harvard Medical School, Boston, MA; Indiana University School of Medicine, Indianapolis, IN. Background: Dr. Robert E. Scully, who recognized and defined gonadoblastoma (GB), used the term "dissecting gonadoblastoma" (DGB) to describe a variant morphology having the same cellular components as GB but with a diffuse or pseudoinvasive pattern instead of the classic nested arrangement. We investigated this pattern and its relationship to classic GB. Design: 48 cases of GBs were identified and evaluated for the presence and morphologic features of DGB, patient age, karyotype, and associated invasive germ cell tumor. Immunohistochemical (IHC) stains for OCT4, inhibin, calretinin, FOXL2, SOX9, SF1, and WT1 were performed. Results: 36 (75%) DGBs were identified. Clinical information was available in 30 patients: age was 3-32 years old (median, 16); 29 were phenotypic females and 1 male; 21 were known to have only 1 X chromosome (16 of which had confirmed Y chromosomes), while 2 others were 46XX. The DGBs consisted of large coalescent nests (solid/expansile pattern), which were often interrupted by fibrovascular septa (92%), of mostly germ cells with minor sex cord cells. Other variant morphologies were small anastomosing nests (anastomosing pattern) and cord-like arrangements (corded pattern) of germ cells with inconspicuous sex cord cells that were irregularly distributed in the stroma. Mixed patterns were seen in 23 DGBs, with solid/expansile usually being predominant. The germ cells ranged from resembling spermatogonia to IGCNU-like; OCT4 was variably positive, staining only the latter type (7/7). The sex cord cells were small with dense, oval or angulated nuclei with inconspicuous nucleoli and positivity for inhibin (9/9, strong), calretinin (3/3, variable), FOXL2 (9/9, strong), SOX9 (9/9, weak and focal), SF1 (8/9, strong), and WT1 (4/7, variable). 21 had invasive germinoma (3 of which with embryonal carcinoma, yolk sac tumor, and choriocarcinoma, respectively); 1 had an epidermoid cyst. Granulomas were present in 25 of 29 invasive germinomas, 5 DGBs, and 4 classic GBs. Fibrovascular septa were also seen in 20 invasive germinomas and 9 classic GBs. Conclusions: DGB is commonly seen in association with classic GB and displays identical IHC features, supporting it as a morphologic variant of GB. DGB often mimics invasive germinoma; the presence of sex cord cells (identification aided by IHC for sex cord markers) and heterogenous germ cells are useful differential features. The lack of a granulomatous reaction also favors DGB over germinoma, and may be especially helpful in the corded pattern of DGB. Between HPV-Positive and HPV-Negative Vulvar Squamous Cell Carcinomas Anthony Karnezis, Angela Cheng, Jessica McAlpine, Dianne Miller, Blake Gilks. University of British Columbia, Vancouver, BC, Canada. Background: Vulvar squamous cell carcinoma (VSCC) is two molecularly distinct diseases separable by etiology, i.e. human papilloma virus (HPV)-positive and HPVnegative VSCC. They differ with respect to precursor lesions (usual vulvar intraepithelial neoplasia, uVIN, and differentiated VIN, dVIN) and possibly clinical outcomes, with evidence suggesting HPV-negative VSCC has a worse prognosis. The ability to study different clinical outcomes requires accurate distinction between the two cancer types which can be difficult by morphology alone. This study compares the accuracy of histomorphology in the diagnosis of HPV-positive vs. HPV-negative VSCC, using p16 immunohistochemistry (IHC) as a surrogate for high risk HPV infection. Design: Vancouver General Hospital Pathology records were searched for cases of invasive VSCC with slides and blocks available for analysis from 1985-2005 (n=193) . Representative H&E sections were examined by two pathologists (ANK and CBG), and tumours were designated as HPV-positive or HPV-negative based on morphologic assessment of both invasive carcinoma and, where present, VIN. For example, welldifferentiated keratinizing pattern or dVIN was considered evidence of non-HPV etiology, while basaloid pattern of VSCC or uVIN was considered evidence of HPVrelated VSCC. Whole slide IHC for p16 was performed using Ventana CINtec antibody E6H4. HPV-positive staining was defined as "block" p16 positivity of the basal cells, with variable extension into the mid or superficial layers. Patchy positivity was not considered true p16 positivity. Background: The diagnostic of endometrial polyp (EP) on endometrial biopsies can be challenging and it is subject to inter-and intraobserver variability. The aims of this study are to evaluate the inter-and intraobserver variability in diagnosing EP, and to determine which of the combined histologic features best predict EP. Design: A retrospective of 104 patients that underwent hysteroscopy or sonohysterography following endometrial biopsy. Histology slides were reviewed by three blinded pathologists to identify the following histologic parameters: (1) thickwalled blood vessels; (2) irregularly shaped and positioned glands; and (3) increased stromal fibrosis. Each specimen was reviewed at least twice and then the discrepant cases by all 3 pathologists to determine intraobserver and interobserver variability. The final diagnosis was compared to the sonohysterographic/hysteroscopic finding which is clinically used to diagnose EP. Sensitivity and specificity as well as positive predictive value (PPV) and negative predictive value (NPV) were calculated using Fleiss's kappa statistics and Kendall's coefficient of concordance. Results: Based on the initial histology report, 57 patients had polyp and 47 patients had other diagnosis, and 38 had lesions on imaging compared to 66 with no lesions. Of those diagnosed with polyp, 19 had lesions on imaging and 38 had no lesions on imaging, for 50.0% [95% CI: 33.4-66.6] sensitivity and 42.4% [95% CI: 30.3-55.2] sensitivity. Intraobserver reliability of repeat evaluations by the same pathologist to identify polyp (if 2 of the 3 criteria were met) was moderate for each of the three pathologists (Fleiss' Kappa 0.49 to 0.66), and agreement among the three pathologists using the first evaluation from each pathologist was significant [Kendall's coefficient of concordance=0.74, p-value < 0.0001]. When the consensus among all pathologists was that at least 2 criteria had been met, the PPV and NPV improved to 43.7% and 66.7%, respectively. Conclusions: The diagnosis of EP on endometrial biopsy is highly subject to inter-and intraobserver variability. Consensus on these cases and the use of at least 2 out of 3 criteria could improve the positive and negative predictive value of diagnosis of EP. This recommendation could prevent the overdiagnosis resulting to unnecessary operative procedures for polyp removal or underdiganosis of EP leading to more physician visits for continued bleeding and more biopsies performed.
Brenner Tumor Lack TERT Promoter Mutations That Are Common in Urothelial Carcinoma
Pallavi Khattar, Jian Zhuge, Wen Chen, John Fallon, Minghao Zhong. Westchester Medical Center at New York Medical College, Valhalla, NY; Washington DC VA Medical Center, Washington, DC. Background: Brenner tumors are uncommon ovarian neoplasms, which have overlapping features with urothelial neoplasms, both morphologically and immunophenotypically. Recently, TERT promoter mutation appears as a biomarker for urothelial carcinoma. However, TERT promoter mutation status has never been investigated in Brenner's tumor. Design: Cases of Brenner tumor were collected. Slides were reviewed and selected to make sure the lesion is at least >20% of all tissue. Macro-dissection was performed in some of cases. Genomic deoxyribonucleic acid (gDNA) was extracted from those tissues. TERT promoter mutations were detected by standard PCR-sequencing. P63, GATA3 and PAX8 immunohistochemical (IHC) stains were also performed. Results: 15 cases of Brenner tumor were collected for this study. The mean age of patient at diagnosis is 45 years (ranging from: 38-76 years). The mean size of tumor is 4 cm (ranging from 0.5-30 cm). All of Brenner's tumors had identical immunophenotype of urothelial carcinoma: positive for P63 and GATA3; negative for PAX8. However, none of Brenner's tumor was positive for TERT promoter mutation. were available for 645 cases. Tissue microarrays were stained for p53, WT-1, CK7, CK20, CDX2, HNF-1, and PTEN. Reviewers were blinded to original diagnosis and to germline mutation status. Included in this study are 65 patients with documented BRCA mutations and a control group of HGSC patients (n=54) with both negative family history and negative germline testing results. Results: A significant number of cases received a revised diagnosis after a review of morphology and IHC (n=128/645, 20%). The most frequently changed original diagnoses were endometrioid carcinoma (n=46/128, 36%), and adenocarcinoma NOS (n=19/128, 15%) -89% were reclassified as HGSC. 15/128 (12%) cases originally diagnosed as invasive adenocarcinoma were revised to borderline tumor. Metastatic adenocarcinoma from the gastrointestinal tract was misclassified as a primary ovarian endometrioid or mucinous adenocarcinoma (n=5/128, 4%). Cases from community hospitals were more likely to have their diagnosis changed compared to those from academic centres (p=0.002). All patients with BRCA germline mutations had High Grade Serous Carcinoma. A morphological review showed that tumor infiltrating lymphocytes (TILs) were more prominent in the tumours of patients with BRCA mutations (p=0.02) compared to the Control group of sporadic HGSC. However, there was no significant difference in tumor grade, architecture, atypia, mitotic count, frequency of giant bizarre nuclei, presence of geographic necrosis, or IHC staining between HGSC patients with and without BRCA germline mutations. Conclusions: IHC studies and review by an experienced gynecological pathologist are critical to correctly classify ovarian malignancies. Diagnoses are more likely to be revised in cases from community hospitals. The quantity of TILs is the only morphological feature that significantly differentiates BRCA germline mutation HGSC from sporadic HGSC. Biomarkers currently commonly used do not differentiate BRCA associated HGSC. Felix Kommoss, Friederike Grevenkamp, Florin-Andrei Taran, Diethelm Wallwiener, Sara Brucker, Sigurd Lax, Friedrich Kommoss, Falko Fend, Annette E Staebler, Stefan Kommoss. University of Tuebingen, Tuebingen, Germany; General Hospital Graz West, Graz, Austria; Synlab MVZ Pathology, Mannheim, Germany. Background: FIGO stage I, type I endometrial carcinomas have an excellent prognosis with 5-yr survival rates of >90%. However, a small subgroup of patients will experience tumor relapse, often with fatal progression. Recently L1CAM was shown to be a prognostic marker that showed clear superiority over the currently used multifactor risk score including histological type, grade and stage. The aim of this study was to evaluate the prognostic significance of L1CAM in a large single center patient cohort study. Design: Patients treated for endometrial carcinoma at University Womens' Hospital in Tuebingen, Germany between 2003-2013 were identified. Histological slides and paraffin material were retrieved, and appropriate tumor blocks were selected for immunohistochemistry after central pathology review. Immunohistochemistry was performed using primary L1CAM antibodies (clone L1-14.10). Cases were rated L1CAM positive if more than 10% of epithelial tumor cells showed positive immunostaining. The Kaplan-Meier method was used for survival analysis. Results: A total of 343 cases of FIGO stage I, endometrioid adenocarcinoma was available for immunohistochemistry. L1CAM staining was found to be positive in 41/343 (12%) cases. 35/41 (85%) only showed focal staining, in the remaining 6/41 (15%) cases, diffuse staining was observed. For all FIGO stage I, type I carcinomas, 5-yr survival rates were 57% for patients with L1CAM-positive carcinomas and 89% for patients with L1CAM-negative carcinomas (p<0.002). In the G1 subgroup, 5-yr survival rates were 57% for patients with L1CAM-positive tumors and 91% for patients with L1CAM-negative tumors (p=0.002). Conclusions: Our study confirmed recent findings of L1CAM being a highly relevant prognosticator in low risk endometrial carcinoma patients. L1CAM might help identify a subset of patients, for whom adjuvant treatment strategies currently reserved for high-risk patients only, might be beneficial.
L1CAM: Promising Prognostic Factor in FIGO Stage
I, Type I Endometrial Adenocarcinomas
Occult Endometrioid Cancer and Occult Serous Cancer of the Fallopian Tubes in Patients With Pure Endometrioid Adenocarcinoma of the Endometrium: A Study of 429 Cases With Complete Examination of the Tubes
Ursula Lang, Joseph Rabban. University of California, San Francisco, CA. Background: The value of complete examination of the fallopian tubes, rather than a representative section, in patients with clinically low stage, pure endometrioid adenocarcinoma of the endometrium is not well known. This study defined the incidence of occult tubal endometrioid cancer and occult tubal serous cancer in these patients and the effect on assignment of site of origin; tumor staging; and behavior. Design: Fallopian tubes in all patients with endometrial adenocarcinoma were thinly sliced and completely examined (SEE-FIM protocol). This study analyzed only patients with pure endometrioid adenocarcinoma and excluded tumors mixed with serous carcinoma, clear cell carcinoma or carcinosarcoma. The anatomic sites of tubal involvement by endometrioid adenocarcinoma, serous tubal intraepithelial carcinoma (STIC), and mucosal atypia that fell short of STIC (serous tubal intraepithelial lesion (STIL) were evaluated, as well as endometriosis in the mucosa, serosa and/or muscularis. The original assignment of primary origin for the tubal tumor and the FIGO stage that was used for clinical management was also used in this study. Adjuvant treatment and patient outcome was recorded. Results: Among 429 cases, 15 (3.5%) had endometrioid adenocarcinoma in the tubes (10 in mucosa with or without tumor in serosa/muscularis; 5 in serosa/muscularis but not mucosa). 11 of these 15 were grossly occult. Only 3/15 had adjacent tubal endometriosis to suggest primary tubal origin and the rest were originally classified as spread of the endometrial tumor for clinical management purposes. 7 cases (1.6% of all 429) (mostly grade 1) would have been assigned a lower FIGO stage for the endometrial cancer without recognition of the grossly occult tubal tumor. 3 of these 7 had chemotherapy; none of the 7 had recurrence (median 1 year follow up, range 0 to 6 yrs). Detached intraluminal tumor (presumed artifact due to uterine manipulator use and excluded from FIGO up-staging) was seen in 48 cases (11%). STIC was present in 1/429 cases and STIL in 6/429 cases. No recurrence was observed in patients with STIC or STIL. Conclusions: Complete examination of grossly normal fallopian tubes in otherwise low stage endometrial endometrioid cancer identifies rare cases of occult tubal endometrioid adenocarcinoma and STIC. The clinical significance requires larger scale long term follow up and so the appropriate assignment of primary origin of tubal endometrioid tumor (tubal versus endometrial) and overall FIGO stage remains controversial.
An Infiltrative Growth Pattern Is Able To Predict Poor Outcome in Stage I Type I Endometrial Carcinomas
Sigurd Lax, Friedrich Kommoss, Friederike Grevenkamp, Felix Kommoss, FlorinAndrei Taran, Sara Brucker, Falko Fend, Diethelm Wallwiener, Stefan Kommoss , Annette E Staebler. General Hospital Graz West and Medical University Graz, Graz, Austria; Synlab, Mannheim, Germany; University Hospital Tuebingen, Tuebingen, Germany. Background: FIGO grading is a prognosticator for type I endometrial carcinoma at stage I, but the assessment of the amount of solid growth and of nuclear atypia may be problematic. Alternative approaches for prognostic factors included the pattern of invasion in a binary grading system and the microcystic, elongated, fragmented glands (MELF) pattern. Recently, the pattern of invasion was shown to be of predictive value for lymph node metastases in cervical adenocarcinoma. The aim of this analysis was to test the prognostic value of the pattern of invasion and the MELF pattern in stage I endometrial carcinoma in comparison to FIGO grading.
Design: 392 endometrial carcinomas from a single institution were reviewed jointly by two pathologists without clinical information on a multi-headed microscope. Histological type, FIGO grade, depth of myometrial invasion, the presence of any LVSI and MELF structures were assessed. In addition, the type of invasion was classified into expansile and infiltrative based on the arrangement of the tumor glands and nests, the tumor borders and the degree of desmoplastic stromal reaction. For statistical analysis the chi squared test and Kaplan Meier survival curves were performed (p<0.05= statistically significant). Results: 363 carcinomas were classified as type I (all endometrioid of usual or special type), of which 295 were G 1, 51 G 2 and 17 G 3 according to FIGO. Median follow up was 3.8 years. An infiltrative pattern was found in 20% of G 1, 38% of G2 and 59% of G3 carcinomas, whereas a MELF pattern was found in 10% of G1, 19% of G2 and 18% of G3 carcinomas. Both FIGO grading and invasion pattern were significant for survival (p=0.001 and p=0.01, respectively) but neither MELF nor LVSI. No significant difference for survival was found between FIGO G1 and G2 carcinomas. Among low-grade (G1 and G2) carcinomas the infiltrate pattern showed a trend for adverse prognosis but without statistical significance. Conclusions: An infiltrative pattern of invasion but not the presence of MELF and LVSI are able to predict poor prognosis in type I endometrial carcinomas. Due to the similar outcome of FIGO G1 and G2 carcinomas a binary FIGO grading (low=G1/2 versus high=G3) should be considered for clinical practice. Conclusions: CA IX expression is seen in both pancreatobiliary and gynecologic carcinomas. While the differences in mean H-score between the two groups are statistically significant, the presence of staining in gynecologic tumors limits the utility of CA IX to distinguish the origin of intra-abdominal carcinomatosis. . In addition to gliomatosis peritonei, the patients were diagnosed with immature teratoma (n=14), mixed germ cell tumor with immature teratoma component (n=6), and mature teratoma with carcinoid tumor (n=1). Gliomatosis peritonei was diagnosed at the same time of ovarian neoplasm in 16 patients, at second-look surgeries in 5 patients (ranging from 4 months to 16 years after the original surgery). High grade glioma arising from gliomatosis peritonei and characterized by increased nuclear atypia, mitotic activity and vascular proliferation was identified in one patient. Immunohistochemical staining for Sox2 was diffusely positive in both immature teratoma (n=4) and gliomatosis peritonei (n=8). Immunohistochemical staining for Oct4 was focally positive (n=2) or negative (n=1) in immature teratoma and negative in gliomatosis peritonei (n=7).
Utility of a Two Antibody Panel for Mismatch Repair Deficiency Screening in Female Genital Tract Carcinomas
Conclusions:
Our data showed that the majority of cases gliomatosis peritonei were associated with immature teratoma or mixed germ cell tumor. Even though gliomatosis peritonei is composed of mature glial tissue, it is important to carefully exam the specimen to rule out associated immature teratoma, which could alter therapy, or very rarely malignant transformation to high grade glioma. Sox2 is expressed in gliomatosis peritonei, suggesting that these glial cells are not terminally differentiated and may have proliferative potential. ) and laterality (89.6%) was not satisfactory. Once PAX8 (rabbit mAb) immunostaining status was combined with tumor laterality, the diagnostic accuracy was dramatically raised to 97.9% with significantly high sensitivity (97.4%) and perfect specificity (100%). Conclusions: PAX8 (rabbit mAb) was a specific marker in differentiating POMTs from extra-genital origin MOMCs. As a simple, convenient and high performance-toprice ratio algorithm, combination of PAX8 (rabbit mAb) immunostaining with tumor laterality should be strongly recommended in our routine practice. LGSC). Each has a broad morphological spectrum, with the ability to mimic features of other histotypes. Historically, this has lead to a relatively high frequency of mixed type carcinoma diagnoses (up to 11%). However, recent immunohistochemical (IHC) studies suggest a much lower incidence. Design: In this study, we reviewed a population-based cohort of 871 cases of ovarian carcinoma and through international collaboration, established a cohort totaling 22 mixed ovarian carcinomas. Molecular differences between the distinct components of each mixed case were interrogated using IHC, NanoString-based gene expression, and Ion-Torrent cancer-gene hotspot sequencing analyses. Results: Mixed ovarian carcinomas were found at a frequency of 1.7% in our cohort when modern diagnostic criteria were applied. EC/CCC mixed carcinomas were seen most frequently (6 cases), however EC/LGSC, CCC/MC and other mixes were also observed (4, 2 and 3 cases, respectively). Seven additional cases were also referred to our study from collaborating centres, including 3 EC/CCC, 3 HGSC/CCC and 1 EC/ CCC/Seromucinous mix. Overall, IHC and molecular data support reclassification of at least 9 of the 22 cases as a single histotype with morphological heterogeneity. Of the remaining cases (2 EC/LGSC, 1 CCC/MC, 6 EC/CCC, 2 HGSC/CCC, and 2 other mixes), some appeared as classic "true" mixed cell type carcinomas while rare cases exhibited unique profiles of IHC, gene expression, and mutation that did not allow a conclusive histotype diagnosis. Conclusions: Our data provide objective support to recent changes in ovarian cancer diagnostic criteria suggesting mixed-cell type carcinomas are not a major subgroup of patients. Immunohistochemical, gene expression, and sequencing data suggest "true" mixed-cell type carcinomas account for less than 1% of total epithelial ovarian cancers. A few commonly used immunohistochemical markers were typically sufficient for classification of diagnostically problematic cases. In fact, there are currently no consensus treatment guidelines for the management of these rare neoplasms. Growth hormone releasing hormone (GHRH) is produced by a variety of malignant tumors and acts as a growth factor in an autocrine/paracrine manner. It requires the presence of its receptor, GHRH-R, to exert its effect on neoplastic cells. In this study we evaluated the expression of GHRH-R in a group of MMMTs. Design: Thirty-one examples of MMMT (uterus 25, ovary 3, uterine tube 2, and pelvic epithelium 1) were retrieved from the files of Department of Pathology at the University of Miami, Jackson Memorial Hospital. Immunohistochemistry was performed on paraffin sections using polyclonal anti-GHRH-R antibody (Abcam, Cambridge, MA) and a polymer detection system. The staining results were evaluated in both epithelial and mesenchymal components of each tumor and recorded as negative, focal or diffuse. The presence of GHRH-R RNA and that of its biologically active splice variant (SV1) were evaluated by RT-PCR in six tumors. Results: Positive reactions for GHRH-R were detected in 30 tumors (96%). The epithelial components were diffusely positive in 23 (74%) and focally positive in 6 tumors (19%). The sarcomatous elements were diffusely positive in 19 (58%) and focally positive in 11 tumors (36%). One uterine MMMT was negative for GHRH-R in both components. RT-PCR was positive for GHRH-R RNA and its splice variant in all six tumors.
Morphologic and Immunohistochemical Re-Evaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma
Molecular Characteristics of Mixed Ovarian Carcinomas
Association of Microscopic Findings of Ovarian High-Grade Serous Carcinoma (HGSC) and Status of BRCA Mutation
Conclusions:
We conclude that GHRH-R is expressed by the majority of MMMTs in both epithelial and mesenchymal components. This finding could potentially serve as a basis for therapeutic approaches using peptide receptor antagonists that have shown significant efficacy in experimental models with minimal pharmacologic side effects (Bellyei S, et al. Cancer Letters: 2010; 293: 31-40 Conclusions: Based on our current knowledge of mucinous ovarian tumors, MBN is essentially benign and mucinous carcinomas are rare. Our data show that upstaging did not occur with MBN, whereas 14% of carcinomas were upstaged after complete surgical staging. Intraoperative frozen section diagnosis of ovarian mucinous tumors can be challenging due to the large size of these specimens and limited sampling that occurs. We found that 23% of cases with a frozen section diagnosis of MBN were upgraded to carcinoma on the final. Overall, our data do not support complete surgical staging for a final diagnosis of MBN, however complete surgical staging for a frozen section diagnosis of MBN may still be warranted since up to a quarter of these cases were changed to carcinoma on final diagnosis.
Utility of Claudin-18 and p16 Immunohistochemistry for distinguishing Gastric-Type Adenocarcinoma From Other Subtypes of Cervical Adenocarcinoma
Daichi Maeda. Akita University, Akita, Japan; University of Tokyo, Tokyo, Japan. Background: Gastric-type adenocarcinoma (GA) is a recently established subtype of uterine cervical adenocarcinoma. Although the typical histological features of GA have been documented, distinguishing GA from other cervical adenocarcinomas is not always easy. Here, we performed comprehensive immunohistochemical analysis of cervical adenocarcinoma in order to establish the best panel of markers for distinguishing GA from other subtypes. Special attention was paid to the expression of Claudin-18 (CLDN18), a novel gastric marker that is expressed in lobular endocervical glandular hyperplasia. Design: Immunohistochemistry for p16, CLDN18, MUC6, HIK1083, MUC5AC, ER, and CDX2 was performed in 63 patients who had cervical adenocarcinomas removed surgically. The case series included 37 usual-type adenocarcinomas (UA), nine non-gastric-type mucinous adenocarcinomas (NGMA), nine gastric-type adenocarcinomas (GA), four adenocarcinomas suspicious for the gastric phenotype, two clear cell carcinomas, one serous adenocarcinoma, and one neuroendocrine carcinoma. Background non-neoplastic endocervical glands were evaluated in 36 cases. Results: CLDN18 is expressed in most GAs (89%), whereas its expression is rare (8%) and often focal in non-GAs. Diffuse expression of p16, which was observed in almost all UAs and NGMAs, was never seen in GAs.
UA 35/37 (95%) 2/37 (5%) 2/37 (5%) 0/37 (0%) 27/37 (73%) 15/37 (41%) 9/37 (24%) NGMA 9/9 (100%) 2/9 (22%) 3/6 (33%) 1/9 (11%) 9/9 (100%) 0/9 (0%) 3/9 (33%) GA 0/9 (0%) 8/9 (89%) 6/9 (67%) 4/9 (44%) 7/9 (78%) 0/9 (0%) 1/9 (11%) Suspected GA 2/4 (50%) 2/4 (50%) 1/4 (25%) 2/4 (50%) 3/4 (75%) 0/4 (0%) 2/4 (50%)
Other adenocarcinomas 4/4 (100%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/4 (0%) Conclusions: GA of the uterine cervix is characterized by CLDN18-positivity and a non-diffuse pattern of p16 staining. A CLDN18/p16 immunohistochemistry panel is useful for distinguishing GAs from other subtypes. Using this panel, we were able to diagnose two of the four adenocarcinomas that were suspected of being the gastric phenotype on H&E sections as GAs. Design: Retrospective cohort of 1200 women who were randomly selected from a series of more than 6000 index cervical pap smears that were either positive or negative for high risk HPV. Patient age, race, history of atopic dermatitis, allergic rhinitis, smoking, body mass index, socioeconomic status, marital status, hormone contraceptive use, and two-year clinical outcomes, including follow-up pap smears, HPV testing, and cervical biopsy results were recorded. All cases with an atopic dermatitis diagnoses (n=74) were confirmed by a dermatologist. Analysis was restricted to white females with documented clinical follow-up, which yielded 577 HPV positive and 583 HPV negative cases for comparison. Associations were tested by X 2 analysis and logistic regression modeling. Results: Atopic dermatitis was more common in the HPV positive group (48/577, 8.3%) compared with the HPV negative cohort (26/583, 4.5%) (p=0.007). Logistic regression analysis revealed an adjusted odds ratio of 3.75 [1.3-10.9] (p=0.02) after controlling for potential confounding variables. Older married women were less likely to be positive for HPV .71]) (p<0.0001). Younger single women were more likely to show persistent HPV infection (p=0.03). Smoking history was not associated with an HPV positive index pap smear, but it was the only covariate that tended to be an indicator of progression to CIN2+ (OR 1.52 [0.90-2.58]) (p=0.12). Conclusions: Atopic dermatitis may be an independent risk factor for high-risk HPV infection, even after controlling for a number of known covariates. However, it does not appear to increase the risk of persistent high risk HPV infection, or progression to high grade dysplasia.
Role of p16 in Downgrading -IN 2 Diagnoses and Predicting Higher Grade Lesions
Kruti Maniar, Beatriz Sanchez, Ajit Paintal, Demirkan Gursel, Ritu Nayar. Northwestern University, Feinberg School of Medicine, Chicago, IL. Background: In 2012, the CAP and ASCCP published the "LAST" recommendations for standardization of reporting terminology for HPV-related squamous lesions of the lower anogenital tract, including the use of a two-tier nomenclature (LSIL/HSIL) to better represent the dichotomous biology of HPV (transient infection vs. preneoplasia). The use of biomarkers, specifically p16 immunohistochemistry, was recommended to distinguish precancer (HSIL) from low-grade (LSIL) and non-HPV-related changes. Our objectives were to determine the frequency with which -IN 2 diagnosis would be downgraded based on the use of p16, and if p16 status was predictive of subsequent higher grade lesions. Design: All available cases from 2009 diagnosed as -IN 2 of the cervix, vagina, vulva, and anus were reviewed, with p16 staining (Biocare Medical, performed in all cases with sufficient material. Slides were independently reviewed by two pathologists, with discrepant p16 interpretations adjudicated by a third pathologist. Medical records were reviewed for any subsequent documented pathology for each patient, and all available relevant surgical specimens reviewed. The proportions of p16-positive (diffuse, block reactivity) and negative (all other expression patterns) cases were determined, and the frequency of a subsequent diagnosis of -IN 3 was compared between the two groups using chi-squared analysis. Results: 200 cases (from 194 patients) diagnosed as -IN 2 with available material were identified-168 cervical, 28 anal/perianal, 2 vulvar, and 2 vaginal. Of these, 32% were negative for p16. 166 patients (86%) had subsequent pathology (with follow-up between 4 days and 67 months), of which 132 were excisional procedures. 18.3% of cases were associated with a subsequent diagnosis of -IN 3 on biopsy or excision, with a frequency of 24.5% in p16-positive cases vs. 4.3% in p16 negative cases (p=0.003).
Conclusions: Approximately one third of -IN 2 diagnoses would be downgraded to LSIL over one year in a busy academic practice based on adherence to the LAST recommendations. The finding that p16 expression is significantly associated with a higher risk for -IN 3 on a subsequent specimen (representing clarification of -IN 2 diagnostic uncertainty, progression of -IN 2, or an unsampled coexisting lesion) suggests that the use of p16 to adjudicate -IN 2 diagnosis as LSIL/HSIL would likely predict lesion potential more accurately and avoid unnecessary excisional procedures for LSIL and/or non-HPV-related changes.
Universal Screening for Gynecologic and Colorectal Cancer: A Single Institution Experience
Brock Martin, Chrisy Mafnas, James Ford, Teri Longacre. Stanford University, Stanford, CA. Background: Routine screening of patients with colorectal cancer (CRC) for Lynch syndrome (LS) has become increasingly common, but routine screening for LS in women with endometrial cancer (EC) is rarely performed. In 2011, leading cancer institutions and public health agencies created the Lynch Syndrome Screening Network (LSSN) in order to promote routine LS screening on all newly diagnosed ECs as well as CRCs. To determine the utility of universal screening for gynecologic cancer patients, we report the results of a universal screening program for EC, CRC, and ovarian cancer (OC) covering a 36 month period at a single institution. Design: All CRCs, ECs and OCs were studied for mismatch repair protein deficiency by immunohistochemistry (IHC) over a 36 month period. All cases with MLH1 deficiency underwent methylation analysis (EC, OC) or BRAF V600E mutation analysis (CRC). A subset also had microsatellite instability studies. Cases were classified as "likely LS-associated" if there was deficiency of MSH2 and/or MSH6, PMS2, or MLH1 in absence of methylation or BRAF mutation. Equivocal cases were classified separately as "requiring further study." All other cases were classified as "unlikely LS-associated." Results: Of 686 CRCs screened, 10.8% had deficient MMR (dMMR) and 7.4% were "likely LS-associated," while 30.4% of 293 ECs were dMMR and 9.6% were "likely LS-associated." Only 3.8% of OC were "likely LS-associated;" all but one were clear cell or endometrioid histology. Conclusions: Universal screening of EC identifies a similar, if not higher rate of likely LS-associated cases when compared to CRC (9.6% vs 7.4%). Universal screening for OC is not cost-effective as most cases that are likely to be LS-associated (3.8% overall) can be identified by screening criteria using age and/or histologic type. Sporadic methylation appears to be increased in EC compared to CRC. Universal screening of EC for LS is practical and cost-effective, especially if a 2-antibody screening protocol is used. Successful implementation requires collaboration among genetic counselors, gynecologic oncologists, and pathologists. 
Results:
The concordance between the original diagnosis and expert review using current morphological criteria was 65% (120/186). The single most frequent misdiagnosis was HGSC diagnosed as EC (19/186, 10%). Of the 5 major histotypes, the lowest concordance was in diagnosis of MC and EC. A review diagnosis of borderline tumour was made in 5% (9/186) of cases originally diagnosed as EOC. IHC was utilized in 51% of cases, most commonly CK7, CK20, CEA, CA125, WT1, ER and p53. Reviewers recommended IHC in 24% cases, most commonly WT1, p53 and ER. Conclusions: Accurate histotype diagnosis of primary EOC is vital for correct patient management including genetic counselling . This study shows a significant level of discrepancy in recognition of all major histotypes. While these results are probably not representative of current diagnostic practice, specifically challenging areas are highlighted. Cost-effective IHC panels for specific diagnostic dilemmas will be proposed. [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] were included in the study. Conventional examination of one H&E longitudinal section was compared to detailed examination with multiple parallel cross sections, post lymph node re-inclusion, plus four level H&E 100mm apart. Results: Vulvarsquamous cell carcinoma cases included unilateral (n=27) and central tumours (n=2), with a median size of 1.9cm. Median depth of stromal invasion was 4mm. Five had lymphovascular and 8 had perineural invasion. The number of SLNs excised per patient ranged from 1 to 6. All were submitted to frozen section evaluation. Occult metastases, not detected in conventional examination, were found in 3 of the cases (10%) by detail examination. They were located in the subcapsular region and measure 0.10mm, 0.42mm and 1.10 mm. Three patients were submitted to lymphadenectomy, and 4 were treated with radiotherapy. Median follow-up was 13.6 months (range 1-129 SO (p=0.2728 SO (p=0. , p=0.1451 . Clinical follow up was available in 32 cases including 13 cases with RD (40%). The mean follow up was 47.6 months (range 2-144). 8 (25%) total patients were dead of disease, including 6 from the RD group. The 5-year overall survival for all patients with RD was 54% and all those without RD was 84% (p=0.0382). All patients who died had invasion and metastatic or recurrent disease. Conclusions: Rhabdomyoblastic differentiation is frequently seen in AS, and can be identified morphologically and with immunohistochemical stains. This finding is significantly associated with underlying myoinvasion and overall survival was lower in this group. Additionally, our series confirm that myoinvasion and SO, are markers of poor prognosis in AS. (1). The size of the mass ranged from 3.5 cm to 15 cm (median 8.8). The lesions were described as grossly myxoid or gelatinous (3), well defined (4), and lobulated (3); None of the lesions exhibited necrosis.Histologically, LLTV were lobulated and composed of variable proportions of mature adipocytes, bland lipoblasts, and spindle cells with short stubby nuclei in a diffusely myxoid background with prominent branching vessels. Nuclear atypia was minimal. No necrosis or mitotic activity was identified. Only 1 of 6 tumors (in a 26 year old patient) was positive for PLAG-1 and Rb1. Rb1 was lost and PLAG-1 was not expressed in all other tumors. Tumors were negative for S100 (4/4), CD34 (3/4), and MDM2 and CDK4 (4/5; one with scattered cell positive for both antibodies). DDIT3 FISH was negative in 2/2 cases. The follow-up interval ranged from 4 months to 6 years (median 4 years). Only one patient developed local recurrence, two years following the excision of the primary tumor. None of the patients developed metastatic disease. Conclusions: LLTV are indolent adipocytic mesenchymal tumors arising in adults. Lack of PLAG-1 expression in the majority of LLTV suggests that these lesions are distinct from "true" lipoblastoma. The loss of Rb-1 in the majority of cases suggests a possible role of 13q chromosomal alterations and a possible relationship with the spindle cell lipoma tumor family. Background: Radiation-induced atypia of normal epithelium and stroma that can mimic neoplasia is reported in many organs, including the cervix, however it has not been studied in the fallopian tubes. To prevent misinterpretation as serous tubal intraepithelial carcinoma (STIC), it would be valuable to understand the range of mucosal and stromal alterations in fallopian tubes from women who received radiation for abdomino-pelvic cancer prior to undergoing a surgery that includes salpingectomy. Design: 52 patients with abdomino-pelvic radiation therapy for cancer of the endometrium (21), cervix (16), colon (11), or ovary(2), or uterine leiomyosarcoma (2) prior to salpingectomy were included. Fallopian tubes were examined for morphologic features of STIC and of radiation atypia: epithelial atypia (nucleocytomegaly, variable nuclear shape/size, nucleoli, smudged chromatin), multinucleation, degeneration, mucosal atrophy, stromal atypia (nuclear enlargement, irregular nuclear contours), stromal fibrosis, and mucosal or stromal inflammation. Results: Mucosal atypia with (7) or without (9) underlying edematous/myxoid reactive stroma was present in 31% (16/52) of patients. Atypia was mild (12/16) or moderate (4/16); mostly unilateral (10/16) but often multifocal (12/16), spanning no more than a few dozen cells in length. Most cases did not exhibit mucosal tufting, budding, or stratification. Atypia involved non-fimbriated tube only (12/16) or fimbriae plus non-fimbriated tube (4/16). Micro-foci of submucosal edematous/myxoid reactive stroma were also present beneath non-atypical degenerating, attenuated or denuded mucosa in 5/52 patients. The reactive stroma often contained chronic inflammation and neovascularization and resembled desmoplastic stroma. Extensive mucosal denudation and stromal edema of the fimbriae was present in 29% (15/52). Stromal atypia was present in 1/52 but none exhibited abnormal blood vessels. None of the cases exhibited severe nuclear atypia, mitoses, hyperchromasia, or increased nucleus to cytoplasm (N/C) ratio. Conclusions: Although mild to moderate mucosal atypia, often accompanied by submucosal reactive stroma, can be seen in fallopian tubes following radiation therapy, the absence of severe atypia, mitoses, and increased N/C ratio distinguishes this alteration from STIC. The presence of multifocal submucosal reactive stroma should not be interpreted as desmoplastic stroma but as an additional feature of radiation-induced alteration of fallopian tubes. We derived a set of endometrial and ovarian tumors (100) with mismatch repair immunohistochemistry, microsatellite status and germline data even when the IHC was intact. The IHC was reviewed by observers (gynecologic and gastrointestinal pathologists) blinded to MSI and germline status. The staining patterns were classified according to the 6 patterns listed above.
Comparison of Different Histopathological Methods for the Evaluation of Inguinal Sentinel Lymph Node in Squamous Cell
The Histologic Spectrum of Adolescent Endometriosis
D e f i n i n g S t a i n i n g P a t t e r n s o f M i s m a t c h R e p a i r Immunohistochemistry in Gynecologic Malignancies
Results:
The best internal control was lymphocytes and benign glands. Endometrial stroma often did not stain and myometrium was often weak in staining intensity. Cases also tended to show a specific heterogenous staining pattern with loss of staining of the basal aspect of the tumor. Pattern 1 was most often seen in MLH1 and this pattern may be associated with miscorsatellite instability but with none of the cases showed germline alteration. Pattern 2 was most often seen with MSH6 This pattern was MSS and showed no germline alteration. We identified 4 cases with pattern 3, 2 of which were tested and showed germline mutation. Cases with pattern 6 when observed were all MSS and germline intact. We identified 2 cases of endometrial cancer in which there were islands of loss of tumor staining with retained expression in lymphocytes and other tumor regions showing staining. This was different form pattern 2 which was more patchy loss. Both of these were unstable and showed germline mutation. One ovarian case was intact despite a strong family history and the patient was found to have a germline mutation.
Conclusions:
There does appear to be more heterogeneity in staining of gynecologic cancers compared to gastrointestinal tumors. Regional as opposed to patchy loss of staining in tumor should be considered highly suspicious. Intact staining does not fully exclude Lynch syndrome.
A Comprehensive Analysis of Placental Insufficiency in Late-Onset Small for Gestational Age Births
Alfons Nadal, Miguel Parra-Saavedra, Francesca Crovetto, Stefania Triunfo, Stefan Savchev, Anna Peguero, Adela Saco, Francesc Botet, Eduard Gratacos, Francesc Figueras. Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain; Hospital Clínic, IDIBAPS, University of Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain; Centro de Diagnóstico de Ultrasonido e Imágenes, CEDIUL, Barranquilla, Colombia; Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy; Catholic University of the Sacred Heart, Rome, Italy; Hospital Clínic, Barcelona, Spain. Background: Late-Onset Small for Gestational Age (LO-SGA) fetuses do not show ultrasound features of placental insufficiency but latent placental insuficiency can contribute to pathogenesis and prognosis. Design: A series of placentas were evaluated from singleton pregnancies of SGA births (birth weight below the 10th percentile) delivered after 34 weeks with normal umbilical artery Doppler (pulsatility index below the 95th percentile), that were matched by gestational age with adequate-for-gestational age (AGA) controls. Middle cerebral and uterine arteries, umbilical vein blood flow and Placental Growth Factor (PlGF) levels in maternal blood were evaluated. Placental lesions were classified histologically according to Redline's classification as maternal underperfusion, fetal underperfusion or inflammation. Perinatal morbidity and neurodevelopmental outcomes at 24 months (age-corrected, applying the Bayley Scale to assess cognitive, language, and motor competencies) were evaluated. Results were compared with placental underperfusion (PUP) signs. Results: A total of 284 placentas were evaluated (142 SGA and 142 AGA). Placentas were smaller and had more lesions, mainly reflecting maternal underperfusion in the SGA group. Among LO-SGA babies, those with PUP had higher perinatal morbidity, more alterations in prenatal ultrasound parameters (high uterine and middle cerebral arteries pulsatility indexes and low umbilical vein blood flow normalized for expected fetal weight) and lower PlGF. Neurodevelopmental outcomes were also significantly poorer.
Conclusions:
In a substantial fraction of near-term SGA babies without Doppler evidence of placental insufficiency, histologic changes consistent with PUP are identifiable and can be prenatally predicted by a combination of parameters (high uterine artery pulsatility index and low umbilical vein blood flow). These infants are at greater risk of perinatal morbidity and abnormal neurodevelopmental outcomes at 2 years of age. Britta Ney, Heiko Schuster, Hans-Christian Boesmueller, Janet Peper, Philipp Wagner, Falko Fend, Stefan Stevanovic, Hans-Georg Rammensee, Annette Staebler. University of Tuebingen, Tuebingen, Germany. Background: CA-125 is a well-known tumor marker used for monitoring the response to therapy and tumor recurrence. Immunohistochemistry demonstrates CA-125 expression in over 95% of high-grade serous ovarian carcinomas. Recently, we have shown that CA-125 is a potential target of tumor-infiltrating T-lymphocytes (TILs) in HLA-ligandome analysis of ovarian cancer. The aim of the current study is to correlate the CA-125 expression pattern with overrepresentation in the HLA ligandome, TIL density and outcome. Design: HLA ligandome analysis was performed for 52 cases of high-grade serous ovarian carcinoma, revealing CA-125 as a major candidate. For validation a tissue microarray was constructed from paraffin embedded tissue of the same cases. We used immunohistochemistry to analyse the expression of CA-125 and number of CD3-positive TILs. In a second, independent analysis of 143 cases with up to 120 months follow-up, the prognostic effect of TILs and CA-125 was evaluated with Kaplan-Meier analysis.
CA-125-Expression in Conjunction With High Numbers of Infiltrating T-Cells Is Associated With Improved Survival in High-Grade Serous Ovarian Carcinoma
Results: In our first case series we found a positive correlation between strong and diffuse expression of CA-125 and high-level presence in the HLA ligandome. In the retrospective series we saw a strong and diffuse circumferential staining pattern of CA-125 in 43 of 134 cases (32.0%), a moderate and non-circumferential staining in 76 cases (56.7%). Only 15 of 134 cases (11.1%) were either CA-125 negative or weakly positive. Survival was significantly better for cases with expression of CA-125 and high vs. low levels of intraepithelial TILs (> 7 per HPF). The 5-year overall survival was 67% vs.28% (p= 0.033, log rank). Conclusions: Our data suggest that CA-125 is an effective target for TILs and a good candidate for multipeptide vaccination of ovarian cancer, based on its robust expression and representation in the HLA-ligandome. The improved prognosis of patients with CA-125 expression and high numbers of TILs suggest a role of CA-125 derived epitopes in the anti-tumor response.
Ovarian Teratomas Associated With Anti-NMDAR Encephalitis Are Distinguished By Hypercellular Glial Tissue Associated With Germinal Center Formation
Amber Nolan, Natalia Buza, Marta Margeta, Joseph Rabban. University of California, San Francisco, CA; Yale University, New Haven, CT. Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare but severe paraneoplastic limbic encephalitis that is often associated with ovarian teratoma in young women. Two features are thought to be suggestive of such teratomas: lymphoid infiltrates involving neural elements and dysplastic neurons. This study compared inflammatory infiltrates (including the FOXP3+ regulatory T cell population), neural tissue sub-populations, and the degree of glial atypia in teratomas with and without anti-NMDAR encephalitis. Design: Lymphoid and neural populations were evaluated in 9 ovarian teratomas in women with anti-NMDAR encephalitis (average patient age 22) and in 51 ovarian teratomas in women without encephalitis (average age 28). The topographic distribution (neural versus non-neural elements), quantity of lymphoid infiltrates and aggregates (with versus without germinal centers), and the morphology and density of the neural tissue components were compared..
Results:
The presence of lymphoid aggregates with germinal centers involving neural elements was higher among teratomas with (8/9) versus without encephalitis (3/51). However, there was no difference in lymphoid infiltrates/aggregates lacking germinal centers, density of CD3+ lymphocytes within neural elements, or the presence of regulatory T cells. CD20+ B cells did not infiltrate the neural tissue in either case, and were more prominent in lymphocytic aggregates with germinal centers. Teratomas with encephalitis exhibited fewer mature neurons in glial tissue (p=0.02) and a significantly more hypercellular astrocytic population (p=0.01). Atypical astrocyte features including increased nuclear size, chromatin clearing, and nuclear contour wrinkling were characteristic for teratomas with encephalitis. Conclusions: Loss of mature neurons and an atypical astrocytic glial population are distinguishing features of teratomas associated with encephalitis. The topographically adjacent finding of lymphoid aggregates with germinal centers suggests a possible immune-mediated mechanism of injury to neural tissues in the teratoma, which may give rise to a paraneoplastic process.
Napsin A Has Utility in the Diagnosis of Clear Cell Carcinoma in the Ovary But May Be Less Valuable in the Endometrium
Mary O'Keefe, Teri Longacre, Christina Kong, Ann Folkins. Stanford University, Stanford, CA. Background: Clear cell carcinoma (CCC) in the female genital tract can be a challenging diagnosis, given the significant morphologic overlap with other high grade carcinomas, but the distinction has important prognostic and therapeutic implications. Recent reports suggest that napsin A may be a sensitive and specific marker for ovarian and uterine CCC. We evaluated the utility of napsin A alone and in combination with HNF-1B, another putative marker for CCC, in the diagnosis of gynecologic CCC. Design: Five tissue microarrays (TMA) were constructed from 600+ endometrial and ovarian neoplasms. Two 1-2 mm cores were included from each case. Each TMA was stained for napsin A and HNF-1B. Napsin A was scored based on granular cytoplasmic staining and classified as positive based on at least 1-10% staining. HNF-1B was considered positive with greater than 10% staining (weak or strong). Dual positivity was also assessed.
Results:
Clear Cell Carcinoma High Grade Serous Carcinoma Interestingly, a significant proportion (about one-third) of mucinous ovarian neoplasms showed positive staining for napsin A in a dot-like perinuclear pattern. The 2 ovarian yolk sac tumors were negative for napsin A. Conclusions: Napsin A staining is not unique to CCC in the female genital tract. Napsin A stained a significant number of uterine serous carcinomas which limits utility in the diagnosis of uterine CCC. However, napsin A is potentially valuable for the diagnosis of ovarian CCC, as staining for this marker was only present in a small percentage of ovarian high-grade serous carcinomas. Further study is warranted to investigate the full spectrum of napsin A staining in mullerian tumors with clear cytoplasm, especially given the rate of positivity in mucinous neoplasms. Results: Fourteen UECC (54%) carried at least one mutation typical of EEC and 40% of the tumors carried more than one of these mutations. The most frequently mutated genes were PIK3R1, PIK3CA and PTEN (37%, 37% and 26% of the cases, respectively). TP53 mutations were found in 7 cases (26%), but in 5 cases they were associated with other typical EEC mutations. Interestingly, CNNTB1 was mutated in only one case (5.26%). Background: Recently several investigators have proposed using markers of cervical squamocolumnar junctional cells (SCJ) including cytokeratin 7 (CK7) to highlight two groups within the CIN1 category with different risks of progression to high-grade disease. Using CK7 we aim to investigate this hypothesis using a prospectively collected dataset with adjudicated diagnoses and approximately 5-years of follow-up. Additionally we aim to further examine CK7 stain patterns in all grades of dysplasia. Design: 326 cervix biopsies were stained with CK7 (100 each of CIN1, CIN2, and CIN3, 25 benign, and one invasive carcinoma). Six cases were cut-through. Cases were independently reviewed for CK7 pattern by two pathologists with discrepancies resolved by consensus. Positive staining was defined as either full-thickness squamous epithelium stain or partial thickness stain with diffuse rather than patchy pattern. Clinical followup was by laboratory chart review of all further cervix pathology. Results: High-grade cervical biopsies were more likely to be CK7 positive (CIN1 59% positive, CIN2 69%, and CIN3 81%). CK7 significantly correlated with tissue diagnosis when comparing CIN1 vs. CIN2/3 (p=0.005) but was not significant for CIN1 vs. CIN2 (p=0.155). When limited to CIN1 cases with clinical follow-up (n=70), there was no significant association between CK7 positivity and future CIN2+/HSIL (OR 0.443 [95% CI 0.11-1.7886]) see Conclusions: In this study we confirm that HSIL lesions are more likely CK7 positive compared to LSIL/CIN1. In a subset analysis of CIN1, there was no significant association between CK7 and outcome. These findings are contrary to those of other researchers who have used a panel of SCJ stains and found higher risk of disease progression in CK7 positive CIN1 cases compared to CK7 negative. As it is possible that the prior studies may have used CIN1 cohorts contaminated with CIN2 cases, further studies of CK7 should use only well-characterized consensus cases given the recognized inter-observer variability regarding these diagnoses. Further, the utility of a biomarker on a single cervix biopsy will always be limited by sampling error as a higher-grade lesion can be present but not biopsied. Background: Lymphangioleiomyomatosis (LAM) is a condition characterized by a proliferation of perivascular epithelioid cells typically affecting the lung, but may also be found in lymph nodes and other organs. Some investigators propose LAM is a low grade, destructive neoplasm capable of metastasis and death while others counter that it is an uncontrolled proliferation of cells best regarded as a disease than a tumor. Regardless, LAM is sometimes seen as an incidental finding in lymph nodes in surgical specimens, particularly those obtained for gynecologic indications. A large study of 22 patients (Matsui et al, Hum Pathol) found that extrapulmonary LAM preceded development of pulmonary LAM by 1-2 years; however, these lesions were often several centimeters in size. To the best of our knowledge, no study has investigated the clinical significance of incidental nodal LAM and whether it is a harbinger of pulmonary LAM. Design: Cases were retrieved with keywords "LAM" and "lymph node." All slides were reviewed and affected lymph node sites, quantity and size were recorded. Immunohistochemical stains for HMB45, melanA/A103 and beta-catenin were performed. Detailed clinical history and follow up were obtained for every case.
Mutational Profile of Undifferentiated Endometrial Carcinoma Suggests Its Origin From Endometrioid Carcinoma
Conclusions
Results: All patients were women whose age ranged 35-71 years (median 59). None had a history of tuberous sclerosis. Sixteen of 17 cases were incidental findings from surgery related to gynecologic neoplasms. The remaining case was for management of only nodal LAM. Affected lymph nodes ranged 1 to 6 representing 2% to 100% of all sampled lymph nodes (total nodes sampled ranged 3 to 52). Mean size was 1 mm up to 22 mm (overall mean 4.6, median 3). Lymph node sites affected were regional abdominopelvic chains routinely sampled in staging operations. HMB45 showed strong, but variable staining, melanA/A103 was very focally expressed or negative whereas beta-catenin showed strong, diffuse cytoplasmic reactivity in every case. Follow up ranged 3 to 123 months (mean 38, median 29). No patient with incidental nodal LAM recurred or developed pulmonary LAM. The one patient treated for nodal LAM of 22 mm in size had local recurrence in her regional lymph nodes. Conclusions: Incidental nodal LAM is not a precursor to development of pulmonary LAM. Nodal LAM of larger size (>20 mm) may show local recurrence. Cytoplasmic beta-catenin expression is a more reliable diagnostic marker than HMB45 or melanA/ A103.
Chorionic Villi Intrusion into Myometrial Lymphovascular Spaces and Deep Trophoblast Infiltration Are Common and Specific Findings in Placenta Creta: A Histopathologic Review of 56 Cases
Carlos Parra-Herran, Bojana Djordjevic. University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. Background: Placenta creta (PC) is characterized by invasion of placental villi into the myometrium in the setting of a dysfunctional or absent decidua. Diagnosis of PC and its subclassification as placenta accreta (PA), increta (PI) and percreta (PP) is important, particularly in cases of hysterectomy due to unanticipated intractable postpartum hemorrhage. Previous studies have documented a significant increase in the amount of implantation site intermediate trophoblast (ISIT) and greater depth of ISIT extension into the myometrium. In addition, we have anecdotally observed chorionic villi in myometrial lymphovascular spaces in cases of PC. The aim of this study was to explore the prevalence and specificity of these features. Design: 56 postpartum hysterectomies, 39 with PC and 17 without were reviewed. PC cases were designated as PA, PI and PP. Villous intrusion into lymphovascular spaces was recorded. Using immunohistochemistry for GATA3, the amount of ISIT (number of positive cells in 5 40X fields) and depth of myometrial infiltration by ISIT (% of myometrial wall thickness and distance of ISIT to closest serosal surface) were assessed. Results: Median gestational ages of the PC group (34.6 weeks, range 19-39) and control group (36.4 weeks, range 17-42) were comparable. Presence of chorionic villi in myometrial lymphovascular spaces was frequent in PC: 23/39 vs 1/17 controls (52.6 vs 5.8%, p=0.0003). This finding was more common in PP (67%) and PI (74%) than in PA (20%, p=0.007). Mean total ISIT number per 5 HPFs was greater in PC (634) than in controls (371, p=0.006). Mean depth of ISIT myometrial invasion was greater in PC (49.1 %) than in controls (13.4%, p=0.002). Likewise, mean distance of deepest ISIT to serosa was shorter in PC (6.3mm) than in controls (21.4mm, p<0.0001). A myometrial depth ³25% was seen in 77.2% PC cases and none of the controls. ISIT distance to serosa £15 mm was seen in 86.3% PC and only 11% controls.
Conclusions:
For the first time, we document the finding of chorionic villi intrusion into myometrial lymphovascular spaces, which is highly specific to PC and particularly common in PI and PP. In addition, assessment of ISIT amount and depth of myometrial invasion using GATA3 immunohistochemistry can assist in the diagnosis of PC. We hypothesize that placental invasion in PC is due, at least partially, to ISIT transformation of low resistance myometrial vessels leading to subsequent protrusion of villi into their lumens, in the context of absent decidua. Background: Ovarian epithelial carcinoma (OEC) comprises a large family of tumors with distinct clinicopathological, morphological, immunohistochemical, molecular, and genetic subtypes. Studies suggest that immune response and the presence of tumor infiltrating lymphocytes (TILs) are associated with longer disease free progression and survival. Furthermore, the presence of TILs can be correlated with the genetic background of the carcinoma, e.g. loss of BRCA1 or mismatch repair (MMR) gene expression. In this study, we sought to comprehensively examine a large set of various OECs for the presence of TILs as well as to determine any association with BRCA germline mutation status and loss of mismatch repair (MMR) protein expression. Design: Formalin-fixed paraffin embedded tissues (n=678) from a wide variety of OECs were obtained as part of population-based familial ovarian cancer study. Known BRCA mutation carriers (n=65) and a control group of HGSC cases with negative family history and germline testing (n=54) were included in this study. Using automated image analysis and manual scoring of tissue microarrays, the number of CD3+, CD8+, Foxp3+, CD68+ cells were enumerated. MMR protein status was determined by manual scoring of MLH1, PMS2, MSH2, and MSH6 immunohistochemistry. Statistical analysis was performed using ANOVA (p<0.05) and Fisher's Exact Test p<0.05).
Results:
The frequency of CD3+ and FoxP+ TILS did not statistically differ between different subtypes of OEC (p=0.66 to p=0.85). Morphologically, increased number of TILs was associated with loss of MMR protein expression in endometrioid OEC (p<0.02) as well as BRCA+ high grade serous carcinoma (HGSC) (p<0.005). Loss of MMR protein expression was found to be more frequent in endometrioid OEC and intact in all serous and mucinous borderline tumors. CD68+ macrophages were found more frequently in BRCA+ HGSC (p<0.045).
Conclusions:
The frequency of TILS and CD68+ macrophages varies amongst different morphological subtypes of OEC and genetic background. This data may provide further insight into the interplay of morphological features, immune response, and genetic factors in determining clinical behavior and patient outcome.
Unusual Variants of Invasive Squamous Cell Carcinoma of the Uterine Cervix
Delia Perez Montiel, Jose Chanona, David Cantu de Leon, Alhely Lopez Arias. Instituto Nacional de Cancerologia, Mexico City, Mexico; Instituto Nacional de Cancerologia, Mexico City, Mexico. Background: Squamous cell carcinoma it is the most common invasive neoplasia of the uterine cervix. They typically have nests, cords, or tongues of irregular borders, anastomosed with stromal reaction or even diffuse cell sheets. The cells show welldefined borders with or without keratin. The morphologic spectrum of these tumors and their variants such as condylomatous, lymphoepithelioma like, squamous transitional, sarcomatoid, verrucopapillary, ISCC with columnar differentiation and basaloid have been described, however, can be quite variable. Design: All cases of invasive squamous cell carcinoma of the uterine cervix accessioned in the surgical pathology files at Instituto Nacional de Cancerologia treated with radical hysterectomy during the period from 2005 to the year 2013 were reviewed. Immunohistochemical stains for P63, P16 and CK5/6 were performed in all cases to confirm the diagnosis. Twenty-seven cases showed unusual cytological features or patterns of growth that could lead to misdiagnosis. Results: During 8-year study period, 96 cases of primary invasive squamous cell carcinoma of uterine cervix were available for review. Twenty-seven cases showed unusual cytological features or patterns of growth that could lead to misdiagnosis. These unusual features included adenoid growth pattern (4), CIN 3 like growth pattern (4), insular (2), micropapillary pattern (1), lace pattern (3), paraganglioma like pattern (1), microcystic pattern (1), pilomatrixoma like pattern (3), acantholytic pattern (3). Unusual cytological features included tumors with clear cells (4), sebaceous like carcinoma (1). In several instances, these unusual morphologic features were initially suggestive of alternative possibilities in the differential diagnosis, including non-invasive lesions, immature metaplasia, adenocarcinoma, neuroendocrine carcinoma or metastatic lesions. Conclusions: Unusual histologic patterns can be identified in up to 28% of invasive cervical neoplasms, therefore, it is important to distinguish these unusual morphologic variants of squamous cell carcinoma of the uterine cervix to avoid misdiagnosis that could lead to change the treatment and prognosis of patients. Background: Verrucous and verrucopapillary lesions of the external genitalia and perineum comprise a spectrum whichis diagnostically challenging. These lesions are problematic because large condylomas can clinically mimic malignancy, and conversely, non-HPV related verruciform lesions can be bland yet have been associated with squamous cell carcinoma (SCC). Moreover, these two categories are often confused with one another. Our goal was to review a series of cases diagnosed as such and to identify parameters useful in their separation. Design: Search of our database between the years of 2005-2014 for the keywords "giant condyloma" (GC) "verruciform", "verrucous", "verruco-papillary" and "verruciform LSC". All cases were reviewed and clinical followup was obtained. HPV analysis status was noted. Results: 36 specimens (diagnostic or follow-up biopsies and/or partial/radical resections) from 22 patients were identified. Data with regard to recurrence or development of carcinoma was available in 15/22 (77%). HPV genotyping was available in four cases. 6 patients had GC. Mean age was 55 (median 60) yrs. The histologic features were marked verrucopapillary architecture, mild basal atypia, and minimal encroachment of stroma; of note, viral cytopathic effect was often absent and effacement of the epithelialstromal interface with inflammation could be seen, and mimicked invasion. Low risk HPV was detected in 3 and absent in 1. Lesions from 2 elderly patients recurred; no subsequent carcinoma was documented. 16 patients had other types of verruciform proliferations, which included verruciform dVIN, verruciform LSC, verrucous hyperplasia and verrucous acanthosis with altered differentiation. Mean age was 71 (median 77) yrs. Despite the absence of atypia (VIN) in many, 10 (62.5%) had verrucous carcinoma or invasive SCC that preceded (by clinical report), coexisted or followed the diagnostic biopsy. HPV testing was negative in 2/2 patients. Conclusions: GC and verruciform proliferations are distinct clinicopathologic entities that often occur in elderly patients and may be confused with one another, as either may lack basal atypia or cytopathic effect. A key distinguishing feature is a more verruciform as opposed to condylomatous growth pattern and abnormal keratinocyte maturation, if present, in the latter. Complete excision of lesions and close followup is advised in the latter as these lesions have a higher rate of associated malignancy. Condylomatous lesions also bear close followup due to the risk of recurrence. The distal fallopian tube has emerged as an important pathogenic site for high grade serous carcinoma (HGSC), both in patients with and without genetic risk factors. Serous tubal intraepithelial carcinoma (STIC) is detected in 5% to 10% of women undergoing risk-reducing salpingo-oophorectomy for mutations in the BRCA1 or BRCA2 genes, and in 20-60% of consecutively examined HGSCs. There is a presumed carcinogenic sequence in the tube, ranging from the p53 signature to low (STIL) and high (STIC) grade tubal intraepithelial neoplasia (TIN). However, the frequency with which this sequence can be visualized in cases of HGSC is not clear.
Clinicopathologic Analysis of Verruciform Proliferations of the
Design:
We searched our surgical pathology files for STICs diagnosed in a two-year period (2012) (2013) (2014) . The slides were reviewed by two pathologists (CC and AP) to evaluate the presence or absence of associated lower grade (TIL) lesions. These were defined as cytologic atypia in the tubal epithelium but with preserved cell polarity, lack of stratified growth and absence of cell exfoliation. Results: A total of 36 cases were retrieved. Nearly one-half (47%) had a spectrum of epithelial atypia in keeping with a gradient of progression from low to high grade TIN. Four (11%) had foci of epithelial changes that would be reclassified as low grade TIN only (they did not fulfill criteria for classic STIC). Fifteen (42%) cases demonstrated the presence of STIC but no other lower grade lesions. The mean age of patients with pure STIC was 64, while the mean age of women with STICs and/or lower grade lesions was 58 (p = 0.11).
Conclusions: This study shows that tubal intraepithelial neoplasia in women with HGSC is a heterogeneous entity and implies that transit times from normal to malignancy could vary considerably across this spectrum. The two groups trend toward different mean ages, and these differences in STIC presentation could reflect different patterns of HGSC evolution. (14), small cell morphology (4), or both (6). 9 tumors had pure NE morphology, while 15 tumors also had one or more other histotypes (14 endometrioid, 1 serous, 1 clear cell, and 1 undifferentiated). LVSI was present in 22 cases, and zonal necrosis in 20. Mitotic figures ranged from 17 to 128 per 10 HPFs (mean, 45). All tumors were positive for at least one NE marker (chromogranin, synaptophysin, CD56) with percentage of positive cells ranging from 10-100%. 13 of 16 cases were cyokeratin positive. Initial diagnoses included grade 3 endometrioid adenocarcinoma (6), undifferentiated carcinoma (5), carcinosarcoma (1), and PNET (1). All pts underwent hysterectomy and bilateral salpingo-oophorectomy. FIGO stage at diagnosis was IA in 3 cases, IB (3), II (2), IIIA (4), IIIB (4), IIIC (3), and IV (5). Tx and f/up information was available for 19 pts. 17 pts received adjuvant chemotherapy and/or radiation therapy. 11 pts died of disease (58%), with a mean survival of 14mos. 1 pt was alive with disease (5%), with a f/up interval of 12mos. 7 pts were disease free (37%), with a f/up interval of 18mos to 11yrs. 2 patients had recurrences at 6mos and 2yrs, but responded to therapy and were disease free at last f/up. Conclusions: EM NECa is a rare disease which affects patients with a wide age range. Most cases are large cell type, and mixed with an endometrioid adenocarcinoma. While EM NECa is an aggressive disease, a third of the patients had long term survival (mean 6.5yrs). There were no morphologic features or clinical parameters such as disease stage or treatment that predicted outcome. Jaime Prat, Monica Pascual-Garcia, Cristina Bertolo, Maria Nagel, Laia Pau, Juan Nieto, Inigo Espinosa, Silvia Vidal 
EWS16T Is a Useful Marker for the Detection of Microsatellite Instability in Endometrial Cancer
Characterization of Tumor Associated Macrophages in Endometrioid Endometrial Cancer
Conclusions:
The most common features of UCA include discohesive cells, geographic necrosis and rhabdoid pattern. Nested, myxoid, signet ring, clear cell and ACA patterns though less common should be included in the morphologic spectrum of UCA. UCA with spindle pattern can be mistaken for CS, but transition with UCA component should alert the pathologist to this variant pattern. We found that more than 75% of patients died of disease within a year of diagnosis, and late recurrences were uncommon (14%). Conclusions: In this cohort of HGSCs, NGS confirms a powerful association between SET morphology and BRCA1 mutations with 67% of SET tumors containing a mutation in either BRCA1 or BRCA2. This underscores the importance of non-classic histology in HGSC and begs the question of whether SET histology reflects a unique target cell susceptibility or differentiation pathway in this population that is not reflected in the other molecular variables. Maria Rolim, Fernanda Silva, Eric Lam, Ana Felix Results: ESS contained tumor in vessels frequently attached to the vessel wall (56%), suggesting a polypoid intrusion into the vascular lumen; small vessels within tumor cell aggregates were present (40%), surrounded by a thin fibrous band at the most invasive leading intravascular front (31%). Immunostains showed endothelial cells lining the vessels and surrounding the intravascular tumor cell aggregates in 100% cases. Only 8 (25%) patients had pelvic(6) and/or lung metastasis (5);only one died of disease.
FOXM1 Immunoexpression in Ovarian Carcinomas
HGS contained tumor in vessels separated from the vessel wall (77%); with no associated stroma or small vessels within the clusters (67%), and surrounding fibrinous reaction around the tumor (16%). Immunostains showed endothelial cells lining the involved vessel but not surrounding the intravascular tumor cell clusters. 33(79%) patients showed pelvic recurrence(13) and/or lung metastasis(27); 21(50%) died of disease, 14(33%) were alive with disease and 7(17%) had no evidence of disease Immunostains showed intravascular tumor foci in veins(72 cases) rather than lymphatics(11 cases). Conclusions: 1. Histologic features including projection of the tumor inside the vascular lumen, tumor cluster containing stroma and/or small vessels and lined by a thin fibrous band of tissue would suggest pseudoinvasion 2. Immunostains for vascular markers would clearly distinguish VI from pseudoinvasion by demonstrating the embolus in reality is covered by endothelial cells that continued from the vessel endothelium 3. Pseudoinvasion(vascular intrusion) can be suspected on H&E, confirmed with immunostains, and can explain cases of "VI" in sarcomas with very low incidence of recurrence/metastasis. 
NP -
NP=not performed
Conclusions: ASPS has a distinct immunophenotype of negative HMB45, melanA and muscle marker expression which distinguishes it from PEComa. Immunohistochemistry, and if necessary, FISH, may aid in distinction of these morphologically similar tumors. Proper identification is important as malignant PEComa may be treated with targeted mTOR inhibitor therapy and ASPS, which is typically histologically uniformly bland, should not be misclassified as benign PEComa. Background: Ovarian and uterine endometrioid carcinomas share histologic and genetic features. In a subset of patients (5-10%), synchronous endometrial and ovarian cancers are found. Independent synchronous primary tumors have been shown to be associated with a favorable outcome compared to that of metastatic disease; hence, an accurate diagnosis is required for optimal patient management. In this study we sought to characterize the repertoire of somatic genetic alterations and to define the clonal relationship of synchronous endometrioid endometrial and ovarian cancers. Design: Five patients with synchronous endometrioid tumors of the uterus and the ovary were included. DNA was extracted from frozen tumor samples and matched normal tissue and subjected to massively parallel whole-exome sequencing (100x coverage). Somatic single nucleotide variants (SNVs) were detected by MuTect, insertions and deletions (indels) by MuTect, Strelka and VarScan2, and copy number alterations by VarScan2 and GISTIC.
TFE3 Translocation Associated Perivascular Epithelioid
Results: All but one tumor pair harbored at least one genetic alteration previously described as a driver genetic event in endometrioid tumors of the uterine corpus and the ovary (e.g. PTEN, ARID1A, CTNNB1, KRAS and PIK3R1). In four cases, 22-106 identical somatic SNVs and indels were found in both tumors, indicating that these shared a common origin and that one was a metastatic dissemination from the other. Large numbers of private mutations restricted to either the endometrial or the ovarian endometrioid tumor were found. Clonal lineage analysis suggested that in these four cases the likeliest primary tumor was the endometrioid endometrial cancer. In one case, however, no somatic genetic alterations were found in common between the two lesion lesions, indicating that these were independent primary tumors.
Conclusions: Synchronous endometrioid tumors of the uterus and ovary are preferentially clonally related and constitute primary tumors and their respective metastases. In one case we have documented the existence of synchronous independent tumors. Clonal lineage analysis provided information about the likeliest order of events. Massively parallel sequencing analysis is a valuable tool to help distinguish synchronous independent primary tumors from metastatic disease, and potentially guide treatment decisions. 28/83) . PNI was correlated with advanced stage (P = 0.021), depth of stromal invasion ³10mm (P = 0.048), lymphovascular invasion (P = 0.001). There was no association between PNI and lymph node metastasis, size of tumor, histologic type and parametrial invasion. Kaplan-Meier curves did show a significant difference in disease free survival (P = 0.046) and overall survival (P = 0.009) on the basis of the presence of the PNI [ Figure 1 ,2]. Binary Logistic regression analysis was carried out to determine a predictive association of the clinicopathological variables with mortality and PNI was found to be an independent prognostic factor (P = 0.013). Conclusions: PNI is associated with multiple high risk factors and is a valuable independent prognostic factor for assessing patients with early stage cervical cancer. Background: Advanced stage tubo-ovarian high-grade serous carcinomas (HGSC) are increasingly treated with neoadjuvant chemotherapy followed by interval debulking surgery. There is no validated system for assessing response to chemotherapy based on histopathological examination of interval debulking specimens. We previously developed a 3-tier scoring system, the Chemotherapy Response Score (CRS), and found assessment of response in the omentum to be superior to that in adnexal tissues in terms of reproducibility and prognostic relevance. In this study we sought to validate this scoring system in an independent cohort of patients. Design: 71 cases of advanced stage high-grade serous carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery were identified. Background: The association of ovarian mucinous tumors with teratomas is well documented, suggesting that at least some ovarian mucinous tumors arise from teratomas. Teratomas -being of germ cell origin -are often genetically distinct from somatic cells, therefore providing a molecular basis for DNA genotyping to separate teratoma-derived mucinous tumors from metastatic ones. We assessed the potential clinical utility of DNA genotyping in the differential diagnosis of ovarian mucinous tumors. Design: Eight cases of ovarian mucinous borderline tumors and three mucinous carcinomas associated with teratomas were retrieved from our departmental archives and the diagnosis was confirmed by reviewing all H&E slides. Target tissues of concern (teratoma, mucinous tumor and paired normal tissue) were microscopically dissected, followed by DNA extraction. Genotyping was performed by AmpFlSTR Identifiler PCR Amplification system, followed by capillary electrophoresis. Results: Of the 8 mucinous tumors, DNA genotyping was informative in five cases including three borderline tumors and two mucinous carcinomas (Table 1) . Homozygosity or partial homozygosity was observed in the teratomatous component in 5 cases and in the mucinous tumor component in 4 cases. Genotypic concordance between the teratoma and mucinous tumor component was seen in 4 cases, consistent with a clonal origin of the two tumor components. One mucinous borderline tumor showed no homozygosity ( Conclusions: When associated with a teratoma, ovarian mucinous borderline tumors and mucinous carcinomas may frequently arise from the teratoma, which was observed in 4 of 5 informative cases in the current study. DNA genotyping may serve as a powerful ancillary marker to confirm the teratoma origin of ovarian mucinous tumors. Fernando Soares, Priscila Saran, Glauco Baiocchi, Elza Fukasawa, Levon BadiglianFilho, Louise De Brot, Claudia Coutinho-Camillo. A.C.Camargo Cancer Center, São Paulo, Brazil . Background: Several cell signals are responsible to enhanced cell proliferation and promoted tumor cell migration and invasion. An appropriate cell-cell adhesion mediated by cadherins is required for the growth, survival and proliferation of epithelial cells. In this study, we investigated the relationship of the loss of expression of E-cadherin (e-CAD) and cell proliferation in neoplastic progression from intraepithelial to invasive carcinoma. Design: We selected from our files cases with histologically normal ectocervix (20 cases), high-grade intraepithelial neoplasia (43 cases), and invasive carcinoma (43 cases). Cases were double stained with e-CAD and Ki-67, and evaluated using colordeconvolution algorithm (Aperio, USA).
Crosstalk Between E-Cadherin Expression and Cell Proliferation in the Progression of Squamous Cell Carcinoma of the Uterine Cervix
Results:
The maximum expression was observed in high-grade lesions with e-CAD preserved and high proliferative index ( figure 1B) . In invasive carcinoma, there are different patterns of expression. Large tumor nests show e-CAD preserved in the central cells of the nest with downregulation in the cell nest limits. The expression of Ki-67 in these large nests showed an inverted pattern: low proliferative index in the central areas, but high proliferative index in cells at the border of the nest ( figure 1C ). When invasive small nests and tumor budding are present, we observed e-CAD downregulation and low proliferative index ( figure 1D ).
The two graphs on figure 2 demonstrated the differences observed in Ki-67 and eCAD expression in the cervical carcinoma neoplastic progression.
Conclusions:
These different patterns demonstrate the importance of adhesion of the tumor cells to proliferate. In conclusion, e-CAD regulation is a very dynamic process during neoplastic progression and cell proliferation is dependent of cell anchorage and preserved adhesion. (Table 1) . A similar increase was not observed in the control group (Figure 1 ). Background: For many years, the designation "granulosa-theca cell tumor" was used for the most common malignant sex-cord stromal tumor. More recently, the designation "granulosa cell tumor" has been preferentially used because the theca component has been considered secondary. We believe based on our experience the older designation has merit for a subset of tumors, having a somewhat distinctive profile. Design: A retrospective five year search of our consultation files was performed to identify granulosa cell tumors with a conspicuous thecoma or thecoma-like component. Basic clinical features were recorded, and the gross and microscopic characteristics of the tumors were evaluated. Results: Twenty-two cases were identified, occurring in patients 12 to 86 years of age (mean 55). Half the patients presented with a pelvic mass; in the others, the tumors were incidental findings. All tumors were unilateral, and with two exceptions, all were 6 cm or smaller. The two larger tumors (13.5 and 18 cm) were mostly cystic with solid components of up to 6 cm. When specimen integrity could be evaluated, nearly all tumors were intact with two being fragmented. The sectioned surface was typically solid and yellow to yellow-white (16/22) with cysts present in six. Low-power microscopic examination showed a predominantly diffuse growth but large typically ill-defined nodules were present in all cases. On higher power, delicate cords were discerned in all cases, often more prominent at the periphery. Classic patterns of granulosa cell tumor (nests, trabeculae, microfollicles) were absent. The tumor cells typically had moderate amounts of pale occasionally vacuolated cytoplasm, but in areas typically judged granulosa in nature cytoplasm was scant. In many areas, distinction between thecoma and granulosa components was difficult and often aided by reticulin stains, demonstrating either prominent intercellular fibrils or a nested pattern. Cytologic atypia was limited (1/22) and mitotic figures infrequent (5/22).
The designation granulosa cell tumor includes neoplasms with a great diversity of gross and microscopic features. A subset, which typically are small (a favorable prognostic feature) and associated with a prominent thecomatous component, represent a somewhat repetitive appearance and on basic principles are likely to have a good outcome and should be designated "granulosa-theca cell tumor" to set them apart from other granulosa cell tumors. Background: There is significant variability in how uterine smooth muscle neoplasms are grossed with significant variability noted regarding how many sections should be submitted when evaluating hysterectomy specimens. Standard practice suggests sampling at least one section of the lesion per largest centimeter dimension of the tumor (1/cm) to ensure that areas of atypia are sampled. Two lesions specifically, atypical leiomyomas (AL) and smooth muscle tumors of uncertain malignant potential (STUMP), can be grossly unremarkable and pathologists strive to ensure that these diagnoses are not missed by sampling smooth muscle tumors extensively. Our goal is to determine the minimum number of slides that could be submitted without missing a diagnosis of AL or STUMP. Design: We retrospectively reviewed 15 cases diagnosed as AL and 10 cases diagnosed as STUMP over the last ten years using set criteria. We then examined how many slides were submitted from the lesion and compared this to how many slides contained worrisome histologic features (WHF). Worrisome features included atypia, mitotic index, necrosis, cellularity, epithelioid growth patterns, and myxoid components. Results: A geometric distribution was used to demonstrate the probability that WHF of AL or STUMP were identified for a given number of slides. The probability of finding WHF, regardless of lesion size, increases with increased tissue submission. Correlation with number of slides submitted and probability of finding WHF are also summarized.
The widespread presence of WHF in these lesions suggests that initial sampling could be reduced, with additional tissue submission if one encounters WHF on initial slide review. The outcome suggests that laboratory costs and time could be reduced without significant detriment to patient care. Jihong Sun, Xiu Yang, Mostafa Fraig, Zhenglong Wang. University of Louisville Hospital, Louisville, KY. Background: It is well known that microenvironment plays essential roles in the progression of precursor or in-situ lesion towards carcinoma. Regulatory macrophage (M2 macrophage) is one of the central regulators. They are recruited and interact with other cells to set up the microenvironment. Although the roles of regulatory macrophage were studied in other organ systems, the understandings of its roles in the progression of endometrial hyperplasia to adenocarcinoma are limited. To address this question, we compare the regulatory macrophages infiltrate pattern between complex atypical endometrial hyperplasia and well differentiated endometrioid adenocarcinoma. Design: Hysterectomy specimens from our institution archives were searched. Eight complex atypical endometrial hyperplasia (hyperplasia group) and nine well differentiated endometrioid adenocarcinoma (carcinoma group) were randomly selected. Formalin-fixed, paraffin-embedded tissues from these specimens were retrieved and stained with antibodies of CD68, CD163, and CD204 to highlight the regulatory macrophages. Five high power views with highest density of regulatory macrophages of each case were selected for quantification. The regulatory macrophages and stromal cells were counted and the percentages of regulatory macrophages were calculated. The student T test was performed.
The Role of Regulatory Macrophages in the Progression of Endometrial Hyperplasia To Endometrial Carcinoma
Results:
The number and pattern of distribution of regulatory macrophages were significantly different between hyperplasia and carcinoma groups. The carcinoma group had significantly higher regulatory macrophages in the stroma (average: 41.7% of stomal cells, n=9) than the hyperplasia group (average: 17.6% of stomal cells, n=8), with P< 0.001. The regulatory macrophages in carcinoma group had a denser infiltration surrounding the tumor glands or nests, whereas the distribution in hyperplasia group had a more diffuse pattern in the stroma. In addition, there were more regulatory macrophages within the glandular lumen in carcinoma group, whereas minimal or no regulatory macrophages were in hyperplasia group. Conclusions: Typically, Endometrioid adenocarcinoma is preceded by endometrial hyperplasia. Characterization of the regulatory mechanisms involving this progression will have significant impacts in patients' management. Our findings demonstrate a significant role of the regulatory macrophages in this critical transition. We will further characterize the involved cytokines and subsets of lymphocytes to elucidate the regulatory networks in the microenvironment of endometrial adenocarcinoma.
Expression Analysis of HPV 16 Encoded microRNAs, HPV16-miR-H1 and HPV16-miR-H2, in Cervical Carcinoma
Suresh Thakur, Snigdha Sahu, Dilip Das, Krishan Kalra. BioGenex, Fremont, CA; Super Religare Laboratories Ltd., Bhubaneswar, Odisha, India. Background: According to the WHO 2013 report, cervical cancer is the fourth most common cancer of the women worldwide after breast, colorectal and lung cancer. Human papillomavirus (HPV) infection is the major cause for all most all the cervical cancer cases. HPV16 and HPV18 types accounts for 70% of cervical cancer. HPV16 type also causes anal and oropharyngeal cancer; more than 50% of the cases of oropharyngeal cancer detected in the United States are linked to HPV16. HPV16 encoded miRNAs were recently discovered by Qian et al, 2013 . Given the importance of HPV16 infection in cancer, in the present study we have evaluated HPV16 encoded miRNAs and miR146a and miR-205 in cervical carcinoma cases. Design: FFPE tissues of Ca cervix (n=20), chronic cervicitis (n=4) and one normal cervix were taken for this study. Expression of p53, ki-67 and p16 was measured by IHC. Detection of HPV16/18 was carried out using a ISH kit from BioGenex. In situ detection of HPV16-miR-H1 (H1), HPV16-miR-H2 (H2), miR-146a and miR-205 was carried out using an ISH probe and detection system (microRNA probes and DF400-50KE, BioGenex). Results: HPV 16 and HPV 18 were found to be positive in the 80% (16/20) of the cases, both HPV types 16 and 18 hand concordance in infection. Chronic cervicitis did not show any HPV16 or HPV18 infection, but p53 and ki-67 expression was seen. HPV 16 encoded miRNAs, HPV16-miR-H1 and H2 were positive in all the Ca Cervix cases where HPV16 was also positive, however expression levels of H2 were higher than H1. One case of Ca Cervix typically showed higher expression of H1 but not H2, p16 expression was also higher but miR-146a and miR-205 were down-regulated in this case. P16, p53 and ki-67 showed moderate to high expression in cervical cancer cases without any significant correlation with miRNA expression. Conclusions: microRNA encoded by virus, may regulate both cellular and viral miRNA and also possibly regulate the switch from latent to lytic infection. HPV16 encoded miRNAs were detected in all the cervical cancer cases infected with HPV16. H2 miRNA expression was higher in comparison to H1. Whether the expression of HPV16 encoded miRNA has role in pathogenesis or switching from latent to lytic infection need to be validated in the larger sample size. Background: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an uncommon undifferentiated ovarian malignancy which presents both diagnostic and therapeutic difficulties. Insights into the tumor have been limited due to its rarity and lack of specific biomarkers to assist in classification and until recently the histogenesis has been completely unknown. Recently it has been shown that germline and somatic SMARCA4 mutations characterize SCCOHT. SMARCA4 encodes the protein BRG1. We showed in a prior publication that 38/40 SCCOHT lacked functional SMARCA4/ BRG1 using genomic analysis and exhibited absence of immunohistochemical staining.
In the current study, we aimed to investigate whether loss of BRG1 protein expression is specific for SCCOHT. Design: The study cohort consisted of morphologic mimics of SCCOHT, including sex cord stromal tumors (adult, juvenile granulosa cell tumor, unclassified sex cord stromal tumor, Sertoli-Leydig tumor and others), undifferentiated carcinoma (UC), neuroendocrine carcinomas (NEC), germ cell tumors (GCT), small round blue cell tumors (SRBCT), including primitive neuroectodermal tumor, Wilms tumor, neuroblastoma and desmoplastic small round cell tumor, and miscellaneous tumors (MIS) such as malignant lymphoma and malignant melanoma. In some cases, whole tissue sections were stained with BRG1. In addition, a tissue micorarray was constructed and stained. The nuclear staining was scored as retained, lost or equivocal, the latter most commonly due to absence of a positive internal control. None=11 Noninvasive=2  Invasive=1  UNK=1   IA=8 IB=1 IC=3  IIC=1 UNK=1   NED=11  UNK=3   APSMT-MI  3  61  None=2  Invasive=1  IA=2 IIC=1  NED=2  UNK=1   APSMT-IC  2  65  None=1  Invasive=1  IIC=1 IIIB=1  NED=1  UNK=1   SMCA  3  61   None=1  Invasive=1  UNK=1   IA=1 UNK=2 NED=1 UNK=2 APSMT = atypical proliferative seromucinous tumor; MI = microinvasion; IC = intraepithelial carcinoma; SMCA = seromucinous carcinoma; NED = no evidence disease; UNK = unknown Conclusions: APSMTs, even those with microinvasion or intraepithelial carcinoma, often present at a low-stage and behave indolently. The pattern of extra-ovarian disease is similar to low-grade serous tumors. The morphology of invasive implants can have architectural and cytologic variability (i.e. psammocarcinoma or cystic masses of mixed cell type). In our study group, seromucinous tumors in patients > 60 years were more often microinvasive, contained intraepithelial carcinoma, or qualify as carcinoma. Results: There were a total of 22 patients who qualified for the study, with a mean age of 34 years, and a range of 20 to 51 years. 21 of the 22 patients showed diffuse strong positive staining for p16. The staining extended for a height of 100% of epithelium in 14/21 patients, and 50% or greater height of epithelium in all 21 cases with strong diffuse staining. Of the 21 patients with strong diffuse staining on cervical biopsy, 10 had CIN III, 6 had CIN II or CIN I-II, 2 had CIN I, and 3 had no CIN on subsequent cone biopsy. The only patient with patchy p16 staining on cervical biopsy had CIN III on cone biopsy. Conclusions: p16 showed diffuse positive staining in almost all biopsies with CIN II and therefore was unable to select for patients with greater likelihood of CIN III in subsequent cervical cone biopsy. Only one biopsy lacked diffuse p16 expressionsubsequent cone biopsy in this case showed CIN III. Our data suggests that each laboratory needs to examine the frequency of p16 staining in their CIN II cases to evaluate potential utility of this marker in their cases for further guiding the decision to perform or not to perform a cone biopsy. If p16 is positive in all or nearly all CIN II cases in a laboratory, it is not going to be a useful maker in that laboratory. There is some evidence of concordance of p16 expression and probability of progression to higher grade dysplasia. However, many CIN II cases negative for p16 progress and vice versa. Additional biomarkers are needed for minimizing the cases that progress with a negative p16 staining and cases that regress with a positive p16 staining. Background: In the era of minimally invasive surgery, a need to identify women with uterine leiomyosarcoma (ULMS) pre-operatively has emerged. While the sensitivity of endometrial sampling (ES) in epithelial-based tumors is well established, the available data for its utility in diagnosing uterine sarcoma is limited. In this study, we attempt to determine the preoperative sensitivity of ES for ULMS and the effect of histologic and clinical variables on the sensitivity. Design: Our retrospective IRB-approved study included all ULMS cases treated at participating institutions between January 2005 and August 2012 (n=329). Cases in which pathologists from the participating institutions had reviewed both the patient's ES and uterine resection specimen were identified. Histologic features of ULMS including grade, presence of necrosis, tumor size, mitotic rate, and lymphovascular invasion were recorded. Data abstracted from the longitudinal medical record included age, presenting symptom, and method of preoperative biopsy. Results: Of 329 cases identified, 24 cases had both ES and uterine pathology reviewed by a pathologist at one of the participating institutions. 15 patients (62.5%) underwent preoperative pipelle endometrial biopsy (EMB), and 9 (37.5%) had dilation and curettage (D&C). 13 (54.2%) of the pre-operative biopsies showed either ULMS or an atypical spindle cell proliferation. Women sampled by D&C were significantly more likely to have a preoperative diagnosis of ULMS than women sampled by EMB (77.8% v 40%, p=0.036 Results: The average age in our cohort was 62.7y (range 27-87y). Histotypes included E (100; 80%: 78 G1, 17 G2, 12 G3, and 2 biphasic G1/3), S (10; 8%), carcinosarcoma (2; 1.6%), U (2; 1.6%), mixed E and S (7; 5.6%), and other mixed subtypes (3; 2.4%). MMR abnormalities included loss of MSH2/MSH6 (3; 2.4%; all E), loss of MSH6 (1; 0.8%; mixed E and U), or loss of MLH1/PMS2 (20; 16%; 19 pure E and 1 mixed E and U). In cases with MLH1 loss, 1 case (5%) was unmethylated. Patients with presumed LS were overall younger than those with MMR-intact tumors (48.5 vs. 62.8y, p=0.006); however, of the 5 cases with presumed LS (loss of MSH2/MSH6, MSH6 only, or MLH1 without promoter methylation), only 3 were < 50 y, (accounting for 27.3% of EMC in women < 50y). None of the patients had a prior history of cancer. The patient with an unmethylated MLH1 deficient tumor had a paternal history of MLH1 germline mutation, and multiple relatives with CRC and EMC. Of the 4 remaining MMR-deficient cases, 1 had a FH of maternal breast cancer, and another had a FH of maternal breast cancer and multiple maternal relatives with EMC. The remaining 2 had unremarkable FH. Tumors with MLH1 methylation were more likely to be G3 (p=0.006).
Conclusions:
Screening guidelines for LS in EMC based on age, FH, and tumor morphology would miss 40% of presumed LS patients at our institution accounting for 4% of EMC. LS-related tumors displayed no prototypical histomorphology. Tumors with MLH1 methylation were the only MMR deficient tumors to display a significantly different morphology, having a statistically significant association with G3 EMC. Our findings support the use of universal screening for LS using MMR IHC in women with EMC.
